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ABSTRACT 
Cardiac hypertrophy is a fundamental response to an increased workload on the 
heart characterized by cardiac myocyte (CM) growth and left ventricular (LV) wall 
thickening. In a model of hypertension, e.g. chronic pressure overload, this process may 
become maladaptive, initially leading to impaired myocardial relaxation and LV filling, 
and subsequently to LV dilation, wall thinning, and contractile failure. Hemodynamic 
overload activates Gαq-mediated signaling responsible for transcriptional reactivation of 
fetal growth programs, activation of the mitogen-activated protein kinase (MAPK) 
cascade, and oxidative stress. The precise mechanism by which MAPK is activated in 
pressure overload, and the role oxidative stress plays in mediating this hypertrophic 
signaling are still under investigation. 
In CMs, the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) 
maintains calcium stores, and thus may regulate calcium-dependent MAPK signaling. 
Our laboratory showed that SERCA is activated in CMs by reversible oxidative post-
translational modification (OPTM) of its most reactive cysteine site (C674). We 
xii 
hypothesized that OPTMs mediate the effects of hypertrophic stimuli in CMs via 
reversible oxidation of SERCA at C674. To test this hypothesis, we employed a 
reductionist model: isolated adult rat ventricular myocytes (ARVM) overexpressing wild-
type (WT) or mutant SERCA, in which C674 is substituted with a redox-insensitive 
serine (C674S). Using alpha-adrenergic receptor (αAR) stimulation as a model of Gq-
mediated hypertrophy, we found that C674S expression decreased both CM growth and 
MAPK activation. Furthermore, biotin switch revealed that αAR stimulation induced a 
reversible OPTM of SERCA at C674. 
We generated a transgenic mouse expressing a single-allele C674S SERCA2 
knock-in mutation (SKI) to explore this mechanism further in the setting of pressure 
overload, a disease model of Gq-activation in vivo. SKI mice subjected to ascending 
aortic constriction (AAC) had decreased hypertrophy compared to WT. Ventricular 
myocytes isolated from adult SKI mice also had diminished MAPK activation in 
response to hypertrophic stimulation in vitro and decreased SERCA function at baseline. 
These findings led us to the conclusion that redox-activation of SERCA via reversible 
modification of C674 is critical for the complete transduction of hypertrophic stimuli to 
MAPK signaling and CM hypertrophy. 
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1. INTRODUCTION 
1.1 Cardiac hypertrophy and hypertension 
Hypertension (HTN), defined as a systolic blood pressure ≥140 mmHg and/or 
diastolic pressure ≥90 mmHg, affected 68 million adults in 2008 in the US alone – 
nearly a third of the adult population – 1 with similar numbers estimated in both 
industrialized and developing countries worldwide.2 Furthermore, of those diagnosed 
with HTN, a third were untreated and more than half were not adequately controlled, 
despite access to care. HTN is the most important modifiable risk factor for the 
development of left ventricular hypertrophy (LVH).3 Although it has long been 
considered a compensatory, adaptive response to HTN, supported by clinical 
evidence that decreased hypertrophy may accelerate the transition to decompensated 
failure,4 LVH itself has been identified as an independent risk factor for multiple 
cardiovascular complications including heart failure, as well as myocardial 
infarction, stroke, and sudden death.5-7 
LVH is characterized by increases in CM size, protein synthesis, cardiac 
remodeling, myofilament reorganization, and reactivation of latent fetal gene 
programs (FGP),8 which have all been suggested to be a compensatory response to 
hypertensive stress.9 Transcriptional changes are observed in genes regulating (1) 
vascular tone, such as atrial natriuretic factor (ANF) and brain natriuretic peptide 
(BNP), (2) CM structure, such as α/β-myosin heavy chain (MHC) ratio and α-skeletal 
actin,10  and (3) calcium cycling, such as the sodium-calcium exchanger (NCX) 11 
and the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA).12 
		
2 
Specifically, α1-adrenergic receptors (αAR) on vascular smooth muscle cells 
are well known to regulate vessel tone and blood pressure,13 and more recently have 
been shown to also mediate cardiac hypertrophy.14,15 Increased production of reactive 
oxygen species (ROS) are also implicated in human hypertension,16,17 LVH,18 and 
αAR signaling, as outlined in chapter 3. 
1.2 Left ventricular hypertrophy (LVH) in animal models of pressure overload 
LVH is a widely-studied phenomenon which occurs in multiple animal 
models of chronic pressure overload (PO), and is almost always associated with up-
regulation of the FGP. Physiologically, PO induced via aortic constriction increases 
cardiac afterload, or the work the myocardium has to exert in order to maintain 
adequate perfusion to end-organs. Animal models of aortic constriction simulate the 
cardiac-specific response to an increased systemic pressure. LVH is a well-described 
response to this increased cardiac afterload in the early stages of PO, and inevitably 
progresses to decompensated failure when chronically uncontrolled. For this reason, 
numerous transgenic models have been elucidated to interrupt this phenotype. 
Gαq receptors, characterized by angiotensin II (AT) receptors, endothelin-1 
(ET) receptors, and αAR on cardiac myocytes, are primary regulators of pro-
hypertrophic pathways in the heart.  Gαq-coupled receptors primarily signal through 
activation of the enzyme phospholipase C (PLC) to generate the second messengers 
diacylglycerol (DAG) and inositol triphosphate (IP3), which releases calcium from 
stores in the endoplasmic reticulum (ER) into the cytosol. These act in concert to 
activate protein kinase C (PKC), with numerous downstream effects. The αAR in 
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particular is also coupled to the mitogen-activated protein kinases (MAPK) by G-
protein coupled receptor (GPCR) activation of RasGTPases, 19  which are also 
upregulated in PO. 20  Transgenic overexpression of the Gαq subunit in cardiac 
myocytes has been shown to be sufficient to induce pathological hypertrophy leading 
to failure,21 and Gαq inhibition22 or knock-out (KO)23 are each able to prevent 
pathological hypertrophy with PO. Unsurprisingly, PO increases expression and 
activity of several downstream effectors of Gαq-mediated calcium release via IP3 
receptors including PKC, 24  calcineurin, 25  and calmodulin-kinase II (CaMKII), 26 
while overexpressing the calcium-sensitive effectors PKC, calcineurin, and Ras27 
have also been shown to induce LVH. 
Interestingly, physiological growth of the myocardium in response to exercise 
training remains intact in Gαq KO models, while expression of dominant-negative 
(DN) phosphoinositide 3 kinases (PI3K) – a GPCR which signals through the kinase 
Akt –28 prevents exercise-induced increases in heart weight, and never progresses to 
failure. These two mechanisms illustrate how two different pathways may be 
responsible for phenotypically similar remodeling with drastically different outcomes 
mediated through opposing signaling molecules.29 
Experimentally modulating the Gαq-coupled receptors themselves also has 
profound effects on PO-induced hypertrophy. While Gαq-coupled AT receptors are 
known to be present on CMs with the propensity to activate MAPK,30 angiotensin 
appears to exert its effects on cardiac hypertrophy chiefly through renal AT 
receptors, which lead to systemic increases in blood pressure (BP).31 Conversely, the 
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catecholamines epinephrine and norepinephrine have been shown to be necessary for 
PO-induced MAPK activation and hypertrophy,32 which is specifically dependent on 
the αAR. αAR KO is a well-documented model of preventing cardiac hypertrophy 
and MAPK activation after only 2 weeks of PO stimulus.14-15, 33-34 
Oxidative stress is also known to play a major role in mediating the Gαq 
response to pressure overload. 35 , 36  Oxidant production from NADPH oxidases 
(NOX)37,38 nitric oxide synthases (NOS), 39,40 and mitochondria41 are upregulated in 
PO. Cardiac-specific KO of the NOX4 isoform prevents hypertrophy in PO, while 
NOX4 overexpression exacerbates this phenomenon and accelerates progression to 
failure. 42  Accordingly, a DN of the antioxidant enzyme thioredoxin-1 (TRX), which 
maintains reducing conditions in the cell,43 exacerbates hypertrophy and increases 
MAPK activation at 2 weeks in PO, while TRX overexpression protects from this 
phenotype.44 Other investigators have found an opposing role for NOX4, suggesting 
its adaptive role in mediating angiogenesis prevents maladaptive hypertrophy in 
PO. 45  Similarly, KO of NOS isoforms prevents hypertrophy.40, 46  Finally, 
overexpression of the antioxidant enzyme catalase, a peroxisomal enzyme which 
catalyzes the breakdown of hydrogen peroxide (H2O2) and localizes to mitochondria 
and SR in the myocardium, 47 reverses both PO48,49 and Gαq overexpression50,51-
induced hypertrophy. These observations occur whether catalase is expressed in 
cytosolic peroxisomes or mitochondrial compartments. Combined, these data 
indicate that regardless of the source of ROS, reducing the redox state of the cell 
appears to universally inhibit hypertrophy. Most of these models appear to exert their 
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reducing affects downstream of PLC, where several redox-sensitive targets have been 
described. 
1.3 Overview of SERCA: function, isoforms, and pathologies 
SERCA is a transmembrane protein, which acts as an inward pump that 
hydrolyzes a molecule of ATP to drive the movement of two intracellular free Ca2+ 
ions into the ER/SR Ca2+ store. Several tissue-specific isoforms of SERCA have been 
described in cardiac tissue. SERCA3, originally thought to be absent from 
myocardium52 is present in a perinuclear distribution in myocytes.53 SERCA2, the 
dominant gene expressed in the heart, co-expresses the cardiac-specific SERCA2a 
major isoform required for normal myocyte contractility, 54  and the ubiquitous 
SERCA2b minor isoform55,56 which maintains ER Ca2+ stores in all cells. 
These two isoforms differ by the C terminus tail, which protrudes into the 
cytoplasm in SERCA2a and crosses back into the ER lumen in SERCA2b.57 
SERCA2b has a greater Ca2+ affinity but decreased catalytic turnover rate58,59 and 
distributes preferentially around SR T-tubules (transversely) in the mouse heart, 
compared to SERCA2a, which is distributed equally longitudinally and 
transversely.60 SERCA2b can re-localize in senescent cardiac myocytes,61 though the 
functional relevance of this is unknown. The differential localization of SERCA 
isoforms suggests that cardiac myocytes may be unique in their potential to maintain 
separate, but inter-connected SR and ER compartments that mediate a) contraction 
via the ryanodine receptor (RyR) and b) intra-cellular signaling via inositol-
triphosphate receptors (IP3R), respectively.62 
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It has been suggested that different SERCA isoforms are localized to different 
regions on ER/SR and possess distinct functions.12 An example of this concept is 
seen in the developing rat heart where Ca2+ cycling involves highly-expressed IP3R 
and SERCA3 on the immature SR, whereas in the adult they are down-regulated and 
replaced by RyRs and SERCA2 that are critical for contraction.63 
1.4 Redox regulation of SERCA activity 
SERCA is functionally regulated by both accessory proteins and post-
translational modifications.64 The accessory proteins phospholamban (PLN) and 
sarcolipin bind to and inhibit SERCA2 when dephosphorylated, 65 , 66  and may 
themselves be redox regulated. 67  Post-translational modifications, such as 
SUMOylation, may also regulate SERCA activity.68 It is now recognized that ROS 
can regulate SERCA activity by way of oxidative post-translational protein 
modifications (OPTM).69 Nitration of tyrosines in SERCA2a decreases activity,70 
whereas OPTM of cysteines can exert bidirectional effects that increase or decrease 
activity. 71 Cysteine oxidation in particular has been described as a redox switch 
which can exert diverse physiological signaling effects.72 SERCA contains several 
potentially reactive cysteine thiols susceptible to oxidative modification,73 the most 
reactive of which is C674,74 making it a prime target for redox signaling. The redox 
susceptibility of C674 is likely due to surrounding tertiary structure, which at 
physiological pH favors the deprotonated C674 thiol, or thiolate. Accordingly, 
decreasing pH has long been known to increase SERCA’s calcium affinity.75 ROS 
can rapidly react with this thiolate to form a range of reversible OPTM including S-
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nitrosylation, S-glutathiolation or sulfenylation.76 In vascular smooth muscle and 
cardiac myocytes, reversible S-glutathiolation of C674 stimulates SERCA and 
SERCA-mediated Ca2+ uptake into stores.77,78 More potent oxidants may cause 
enzymatically-irreversible C674 sulfonylation which prevents SERCA activation,79,80 
decreases maximal Ca2+ uptake activity,81 depletes Ca2+ stores,82 and possibly leads 
to protein degradation.83 As described above, catalase overexpression in PO prevents 
this irreversible OPTM and associated functional decreases in SERCA.48 Myocardial 
tissue samples from patients with advanced heart failure confirm the presence of an 
irreversible SERCA C674 sulfonylation in humans. The dichotomy of oxidative 
states likely stems from the fact that the functional effects of OPTM have been 
associative and indirect, using cell culture models with reductive enzyme over-
expression systems. While OPTM-associated modulation of SERCA function has an 
established role in regulating rapid Ca2+ cycling necessary for excitation-contraction 
coupling in CMs,84 it is not known whether this change in cardiac pump function can 
regulate cardiac myocyte growth. 
1.5 Role of SERCA in cardiac hypertrophy 
While SERCA transcription, protein level, and/or function is variably 
reported to be decreased in late models of PO-induced decompensated failure, 
SERCA levels are preserved during the initial hypertrophic phase early after 
ascending aortic constriction (AAC),85 and transgenic overexpression of SERCA2a 
does not rescue this phenotype.86 In fact, one model of PO even found that SERCA 
function was increased at one week.87 Furthermore, complete KO of SERCA2 in the 
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PO-heart accelerates failure without inducing LVH, suggesting that SERCA is 
required for the hypertrophic phase preceding apoptosis and failure.88-90 
While evidence for human mutations of the SERCA2-encoding gene, 
ATP2A2, exist in a clinical syndrome known as Darier’s disease, currently these 
alterations have only been associated with alterations in epidermal differentiation.91 It 
has been proposed that compensation for the mutated SERCA2b by abundant 
SERCA2a expression in the heart may preserve CM dysfunction.92 In addition, a 
relationship between abnormal cell proliferation and SERCA pump dysfunction has 
been reported in cancer cells,93,94 indicating that altered calcium homeostasis due to 
SERCA can mediate growth signaling effects. Furthermore, growth signaling in 
endothelial cells (EC) requires SERCA C674 S-glutathiolation,95 which is mediated 
by NOX4.96 Although SERCA overexpression does not prevent PO-induced LVH, 
overexpression of a modified SERCA isoform with higher calcium affinity does 
attenuate the hypertrophic response to PO. 97  Similarly, disrupting the splicing 
mechanism for generation of the SERCA2a isoform in the mouse heart causes a 
compensatory overexpression of the higher-affinity SERCA2b and leads to up-
regulation of FGP and hypertrophy due to increases in CM size.98 Though total 
SERCA2 levels only compensate to about half of wild-type levels in this model (with 
consistently decreased Ca2+ uptake), cardiac myocyte growth does not occur in the 
heterozygote SERCA KO. 99  Finally, expression of SUMO-1 prevents oxidant-
induced changes in SERCA function and blocks both CM hypertrophy, protein 
synthesis, FGP upregulation, and MAPK activation in response to the αAR 
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phenylephrine (PE) in vitro, as well as LVH with PO in vivo.100  Each of these 
observations suggests SERCA function may play an important role in hypertrophic 
growth in CMs.  
While clinical and animal models have attempted to restore SERCA in 
hypertrophied and failing hearts,101,102 these may be associated with increased energy 
demand in hearts with LVH and limit their beneficial effects.103 
1.6 Hypothesis 
Oxidation of SERCA regulates hypertrophic growth in cardiac myocytes. 
1.7 Specific aims 
1.7.1 Aim 1 
We tested the hypothesis that αAR in vitro requires SERCA C674 to 
mediate CM hypertrophy and MAPK activation via SERCA oxidation. 
1.7.2 Aim 2 
We tested the hypothesis that AAC in vivo requires SERCA C674 to 
mediate LVH via SERCA oxidation. 
1.7.3 Aim 3 
We developed probes to test the hypothesis that Gαq-mediated redox 
activation of SERCA modulates calcium signaling. 
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2. MATERIALS AND METHODS 
2.1. Cardiomyocyte isolation and culture 
2.1.1. AMVM 
LV myocytes were isolated for signaling and contractility experiments 
using previously described methods, with some modifications.104 Briefly, 
mice were intraperitoneally heparinized with 200 U heparin and anesthesized 
with isofluorane. Hearts were rapidly excised, cannulated via the aorta and 
perfused in the Langendorff mode, at a rate of 3mL/min at 37°C. Hearts were 
initially perfused for 3-5 min with a Ca2+-free Tyrode isolation solution (IS; 
137mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 2.4 M HEPES, pH 7.62) 
supplemented with 10 mM glucose, 5 mM taurine, 10 mM 2,3-butanedione 
monoxime (BDM) and probenecid, with a final pH of 7.37.  Hearts were then 
perfused with a digestion buffer containing 0.05% collagenase B, 0.05% 
collagenase D (Boehringer Mannheim) and 0.01% protease XIV (Sigma). 
After the hearts were palpably flaccid (typically between 6–8 min), they were 
removed from the cannula and the LV was separated using forceps, minced, 
and gently agitated, allowing the myocytes to be dispersed and filtered 
through a 100µm filter. After 15 minutes, the dissociated cells were 
resuspended in 1% BSA containing IS, and gradually sedimented by gravity at 
5-minute intervals with increasing [Ca2+] (0.06, 0.24, 0.6 and 1.2 mM CaCl2, 
pH 7.4 at room temperature). Myocytes were plated in 35mm plastic dishes 
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for signaling experiments and culture chambers (Cell MicroControls) for 
contractility studies. 
2.1.2. ARVM 
Calcium-tolerant adult rat ventricular myocytes (ARVMs) were 
obtained from hearts of male Sprague-Dawley rats (175 to 200 g, Harlan). 
Animals were anesthetized with isofluorane and their hearts were aseptically 
removed into Ca2+-free Krebs-Henseleit buffer (KH: 118 mM NaCl, 4.75 mM 
KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 48mM dextrose, 
pH 7.4). The hearts were retrograde-perfused at a rate of 7.5-8 mL/min on a 
Langendorff apparatus with KH for 2 minutes at 37°C. The perfusion solution 
was then switched to a recirculating KH solution containing the digestive 
enzymes collagenase Type II (0.34-0.38 mg/mL, Worthington) and 
hyaluronidase Type II (0.14-0.15 mg/mL, Sigma) for 17 minutes. After 
perfusion, hearts were halved, quartered lengthwise, and minced into 
longitudinal strips. Cells from the left ventricle were released by shaking the 
tissue in the KH digestion buffer supplemented with DNAse (0.02 mg/mL, 
Worthington), Trypsin Type IX (0.02 mg/mL, Sigma), and 1 mM CaCl2 in a 
37°C shaking H2O bath for ~25 minutes, and then centrifuged at 50 x g for 3 
minutes. The pellet was filtered through a 100-µm mesh filter and allowed to 
settle (10 minutes) in wash buffer (50% KH, 50% DMEM). This pellet was 
then resuspended in DMEM (Gibco), layered over 0.0645g/mL BSA (Sigma) 
to separate ventricular myocytes from nonmyocytes, and allowed to settle for 
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10 minutes. The final pellet was resuspended in ACCT medium consisting of 
DMEM containing 0.2% BSA (Sigma), 2 mM L-carnitine (Sigma), 5 mM 
creatine (Sigma), 5 mM taurine (Sigma), 2.5 M HEPES and 100 U/mL 
penicillin-streptomycin (Gibco). The ARVMs were then plated in ACCT 
medium at a density of 30-50 cells/mm² on 60-mm, 35-mm or 6-well plastic 
culture dishes (Fisher) or 35-mm glass bottom culture dishes (MatTek) 
precoated with laminin (10 ug/mL, Invitrogen). After 1 hour, the dishes were 
washed with ACCT to remove cells that were not attached. The remaining 
cells were maintained in ACCT medium for 16 hours before the addition of 
phenylephrine and blocking drugs. 
2.2. Adenoviral constructs and ARVM infection 
Adenoviral vectors encoding human SERCA2 (WT) and human mutated 
SERCA2 (C674S), as well as the cameleon constructs D1ER and 4mtD3cpv were 
constructed as previously described.79 Briefly, full-length human SERCA2b 
constructed in pcDNA 3.1 and mutagenesis of cysteine-674 was performed using 
the Stratagene mutagenesis kit. Cameleon constructs were graciously contributed 
by Dr. Roger Tsien, University of California San Diego. The inserts of SERCA 2b 
WT, SERCA 2b C674S, cameleon D1ER, and cameleon 4mtD3cpv were excised 
from pcDNA3.1 using PME-1 and ligated into the EcoRV site of pShuttle, which 
uses the cytomegalovirus (CMV) promoter. The correct direction was confirmed 
by enzyme restriction analysis as well as sequencing. This shuttle vector was co-
transfected into E. coli with pADEasy, the appropriate cosmids were cut by PAC-
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1 digestion and transfected into HEK-293 cells using calcium phosphate, and 
adenoviral plaques were selected. The adenovirus was propagated in HEK 293 
cells and purified via a double cesium chloride gradient to remove noninfectious 
empty capsids.105 The viral titer was determined using the TCID50 method. An 
adenovirus encoding β-galactosidase (lacZ) was used as a control in all signaling 
experiments. ARVM were infected with WT SERCA (MOI = 100) or C674S 
(MOI = 100), equivalent to approximately a 12-fold overexpression vs 
endogenous SERCA (p < 0.01, n = 3) or D1ER or 4mtD3cpv for 36 hours. 
Uniformity of cameleon expression was not assessed due to the ratiometric nature 
of the probe. 
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Figure 1. SERCA2 overexpression in ARVM 
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2.3. Adeno-associated virus construction and tail-vein injection 
Adeno-associated virus (AAV) vectors for the cameleon contructs D1ER 
and 4mtD3cpv were generated with the pcDNA excision protocol outlined in 2.2: 
Adenoviral construction, and inserted into AAV vectors. Human 293 cells were 
plated at 20-40% confluency and allowed to grow to 80% confluence in 30 225-
cm2 flasks over a period of 24-48 hours. 23 µg of AAV vector and rep and cap 
helper plasmids were added to 300 mM CaCl2. These genes together with E1 
from the 293 cells together encode the genes sufficient for AAV replication. This 
solution was added to an equal volume of 2x HBS (290 mM NaCl, 50 mM 
HEPES, 1.5 Na2HPO4, pH 7.1) and pipetted into the flask in DMEM/F12 plus 
10% fetal calf serum (FCS). The plate was incubated at 37°C for a further 4-6 
hours, after which media was replaced with 2% FCS DMEM. Three days after 
transfection, 1 mL of 0.5 M EDTA (pH 8.0) was added to the flask and incubated 
at RT for 3 min. Cell suspensions were collected and centrifuged at 300 x g for 
10 min. Supernatants were removed and cell pellets resuspended in 2 mL TBS. 
Cells were then freeze-thawed three times and subsequently centrifuged at 
10,000 x g to remove cellular debris, and supernatants collected. 
 Pooled supernatants were overlaid onto a solution of 40% sucrose plus 
0.01% BSA in TBS in a sterile ultracentrifuge tube (Ultrabottle, Nalge Nunc), 
and crude viral particles pelleted by centrifugation at 100,000 x g for 16 hours at 
4°C. The pellet was resuspended in 5mL DNAse buffer (50 mM HEPES pH 7.6, 
0.15 M NaCl, 10 mM MgCl2) with 1,000 units of DNAse I and incubated for 1 
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hour at 37°C. 0.5 M EDTA was added and the solution was centrifuged at 10,000 
x g for 2 min to remove debris. The supernatant was subsequently filtered 
through a low-protein-binding 5-µm syringe filter (Pall Gelman) and loaded onto 
a two-tier CsCl gradient (1.25 g/mL and 1.50 g/mL) in HNE buffer (50 mM 
HEPES pH 7.4, 0.15 M NaCl, 25 mM EDTA). This gradient was centrifuged at 
35,000 rpm for 2 hours at 16°C in a SW40 rotor (Beckman), and viral fractions 
were collected and loaded onto a second CsCl gradient. This gradient was 
centrifuged at 65,000 rpm for 2 hours at 16°C in a VTi65.2 rotor (Beckman) and 
viral bands were collected. Viruses were then dialyzed with Slide-A-Lyzer 
dialysis casettes (Pierce) to desalt the virus by three cycles of dilution with HNE 
buffer at 4°C. The final titer was quantitated using the QuickTiter AAV 
Quantification Kit (Cell Biolabs, Inc.). Tail veins of WT and SKI mice were 
injected with AAV and myocytes were isolated as described in 2.1.1. AMVM, 
following 2 weeks of infection. 
2.4. 3H-Leucine incorporation 
ARVM infected with lacZ, WT SERCA2b, and C674S SERCA2b 
adenovirus were plated on six-well laminin coated dishes and protein synthesis 
was measured. Cells were stimulated with PE (10 µM) in the presence of 
[3H]leucine (2.5 µCi/mL) for 36 h. The cells were then washed twice with ice-
cold PBS followed by incubation with 5% trichloroacetic acid (TCA) for 30 min 
to precipitate proteins. The precipitates were washed twice with cold water and 
resuspended in 2 mL 0.4 M NaOH. Aliquots were quantified by scintillation 
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counting (dpm/well). The total protein concentration was measured by the 
Bradford method (BioRad). 
2.5. Western blotting 
Mouse myocytes from WT and SKI mice plated on 35-mm laminin-
coated culture dishes were treated with norepinephrine (1 µM, 15 min, Sigma) 
after 30 min pretreatment with propranolol (2 µM, Sigma), or ARVM infected 
with lacZ, WT SERCA2b, or C674S SERCA2b adenovirus plated on 60-mm 
laminin-coated culture dishes were treated with phenylephrine (10 µM) for 5 
min. Cells were then washed with ice-cold PBS and lysed in Cell Lysis Buffer 
(20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4, 1 ug/mL leupeptin, Cell Signaling) supplemented with PMSF (1 mM) 
and needle-lysed with a 31½-gauge insulin needle to shear DNA. Soluble lysates 
were separated by microcentrifugation, and volume representing equal amount of 
proteins were boiled at 95°C for 10 min before being resolved by 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins 
were transferred to Immobilon-FL PVDF membranes (Millipore), blocked with 
Licor Odyssey blocking solution (Licor) for 1 hour at room temperature, and then 
incubated with the primary antibodies outlined in Table 1 at 4°C overnight. 
Protein was detected with IRDye® 680RD goat (polyclonal) anti-mouse IgG (H + 
L) or 800CW donkey (polyclonal) anti-rabbit IgG (H + L) infrared (IR) 
conjugated secondary antibodies (Licor).  
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Table 1. Primary antibodies used to evaluate MAPK and other signaling cascades. 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) 
pAb rabbit Cell Signaling 
p44/42 MAPK (Erk1/2) mAb mouse Cell Signaling 
Phospho-MEK1/2 (Ser217/221)  pAb rabbit Cell Signaling 
Anti-MEK1 mAb mouse BD Biosciences 
Phospho-c-Raf (Ser289/296/301) pAb rabbit Cell Signaling 
Phospho-c-Raf (Ser259) pAb rabbit Cell Signaling 
Phospho-c-Raf (Ser338) (56A6) mAb rabbit Cell Signaling 
c-Raf (D5X6R)  mAb mouse Cell Signaling 
Anti-phospho-PKCα (Ser657) pAb rabbit Millipore 
Anti-PKCα, clone M4 mAb mouse Millipore 
Phospho-CAMKIIβγδ pThr287 pAb rabbit ThermoScientific 
CaM Kinase II (6G9) mAb mouse ThermoScientific 
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2.6. Ras activity assay 
Activated Ras was detected by Ras Activation Assay Kit according to the 
manufacturer’s instruction. Briefly, cell lysates (500 µg) were 
immunoprecipitated at 4°C overnight with agarose conjugated anti-Raf-1 
antibody corresponding to the human Ras binding domain (RBD) of Raf-1. The 
immunoprecipitates were resolved by 10% SDS-PAGE and detected by Western 
blot analysis using anti-Ras antibody. 
2.7. Biotin switch assay 
Reversible oxidative cysteine modifications of SERCA were assessed 
using a biotin switch assay. ARVM infected with lacZ, WT SERCA2b, or C674S 
SERCA2b adenoviruses on 60-mm laminin-coated culture dishes were treated 
with 10 µM PE for 5 minutes and washed with ice-cold phosphate-buffered 
saline (PBS). From this point on, all materials containing cells and lysates were 
protected from light to prevent premature degradation of alkylating compounds. 
Cells were lysed in a solution of Tris-buffered saline (TBS) containing the 
detergent sodium dodecyl sulfate (SDS, 2%) and the alkylating agent n-
ethylmaleimide (NEM, 100mM) to block all free sulfhydryl moieties. Lysates 
were incubated at room temperature (RT) for 1 hour, and subsequently spun at 
maximum speed on a tabletop centrifuge at 4°C for 15 minutes. Supernatants 
were layered atop Zeba™ Spin Desalting Columns (7K MWCO, 0.5mL, 
ThermoScientific) previously buffer exchanged with a cell lysis buffer to 
maintain protein solubility (RIPA, 20 mM Tris-HCl pH 7.5, 150 nM NaCl, 1 mM 
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Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, 
Cell Signaling) to remove excess NEM. The alkylated lysates were subsequently 
incubated with dithiotreitol (DTT, 5mM) for 1 hour at RT to reduce reversible 
OPTM, and column-cleaned. The reduced lysates were then incubated with 
biotinylated-iodoacetamide (BIAM, 1 mM) for 1 hour at RT to permanently label 
all reversibly modified sites. BIAM-labeled lysates were column-cleaned one 
final time and incubated overnight at 4°C in a solution containing magnetic 
streptavidin sepharose beads pre-washed in RIPA buffer. Supernatants containing 
un-labeled proteins were removed and run on SDS-PAGE simultaneously with 
beads bound to BIAM-labeled proteins washed in PBS containing 300 mM NaCl, 
and resuspended in Laemmli buffer containing the reducing agent β-
mercaptoethanol (β-ME, 6 mM). Membranes were assessed for BIAM-labeling 
of SERCA by incubation with primary SERCA2 monoclonal mouse antibody 
(2A7-A1, ThermoFisher), which recognizes both endogenous rat and 
overexpressed human SERCA2 isoforms. 
2.8. Cardiomyocyte contractility 
Freshly dissociated mouse LV myocytes were loaded with membrane-
permeant fura-2/AM (1 µM, Molecular Probes) for 20 min at 37°C. After 
washing out Fura-2/AM in the loading solution, an additional 20 min was 
allowed for de-esterification of the fura-2 ester within cells. 500 µM probenecid 
was included throughout this procedure to prevent the leakage of fura-2 from the 
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cells. Fura-2 loaded myocytes had 4-5 times 360 nm-excited fluorescence over 
background. Cells were superfused with 1.2 mM Ca2+-Tyrode solution, pH 7.4 at 
37°C. The cells were electrically stimulated via platinum wires at an initial 
pacing rate of 2 Hz for 15 min to establish steady-state conditions, and cell 
shortening and fura-2 fluorescence ratios were simultaneously recorded. The 
pacing rate was subsequently increased to a physiological rate of 5 Hz with 2 min 
of stabilization prior to recording cell shortening and fura-2 fluorescence. 
Myocytes included in this study were selected using the following criteria: (1) 
rod-shaped with a clear striation pattern (no granulation and no cauliflower-
shaped cell ends); (2) quiescent when unstimulated; and (3) stable mechanical 
behavior at 5 Hz and 37°C for 10–15 min. No cells were used past 6 h post-
isolation. 
Resting cell length and width were determined by video edge-detection 
and resting sarcomere length was determined from discrete striation positions on 
the myocyte using real-time power spectrum analysis software (IonWizard® 
video-edge detection and fluorescence system, Ion-Optix Inc.) Percent cell 
shortening (% CS) was calculated as diastolic cell length minus systolic cell 
length normalized to the diastolic cell length. The time constant (τ) for myocyte 
relengthening and the calcium transient decay were calculated. Cytosolic calcium 
was measured by the fluorescent calcium indicator fura-2 using a dual 
fluorescence, calcium ion sensing system (IonOptix). The fura-2-loaded 
myocytes were excited at 360 and 380 nm. Emission fluorescence was measured 
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at 510 nm. The fluorescence ratio, F360/F380, is independent of the intracellular 
fura-2 concentration, cell geometry and excitation light intensity, and reflects the 
intracellular calcium concentration. Myocytes were alternately excited with an 
ultraviolet (UV) xenon lamp at wavelengths of 360 and 380 nm through filters 
installed on a rotary wheel controlled by the data acquisition system. Photons 
counted by the photomultiplier tube were collected simultaneously with the cell 
shortening signal by the data acquisition system provided by IonOptix. 
2.9. Generation of the SKI mouse and statement on animal use 
The SERCA 2 C674S heterozygote knock-in mouse (developed in 
collaboration by Dr. Richard Cohen, Boston University School of Medicine)106 
was generated on a C57BL/6J background by inGenious Targeting Laboratory, 
Inc. A mutated 14.4 kb SERCA exon 14 containing the Cys-674 to Ser-674 codon 
(TGT→TCC) was inserted into the endogenous SERCA2 gene locus. In this 
construct, a neomycin cassette was introduced into the intron between exon 14 
and exon 15 for embryonic stem cells selection. The neomycin cassettes were 
removed in vivo by breeding in flp recombinase, and the recombinase was bred 
out by another round of breeding, all while maintaining the C57BL/6J genetic 
background of the original embryonic stem cells used. This mouse was validated 
for absence of extra DNA inserts. Expression of the mutant allele is governed by 
the unaltered upstream native SERCA 2 promoter. The presence of the C674S 
mutation was confirmed by sequencing of genomic DNA. Homozygous knock-in 
fetuses died in utero just prior to the initial period of cardiac development (8–10.5 
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days), so only heterozygous adult animals expressing 50% of SERCA 2 C674S 
allele were studied. All animal usage was approved by Boston University's 
Institutional Animal Care and Use Committee in accordance with the provisions 
of the Animal Welfare Act, Public Health Service Animal Welfare Policy, the 
principles of the NIH Guide for the Care and Use of Laboratory Animals, and the 
policies and procedures of Boston University Medical Campus. Animals were 
maintained in an AALAC approved Laboratory Animal Science Center staffed 
with licensed veterinarians. 
2.10. Ascending aortic constriction model of LVH 
Transgenic C57BL/6 mice with whole body expression of SERCA C674S 
(SKI) and wild-type (WT) C57BL/6 mice were used in this study. The protocol 
was approved by the Institutional Animal Care and Use Committee at Boston 
University School of Medicine. The surgical procedure was performed as we have 
described.48 Briefly, 8-10 week-old male and female WT and SKI mice were 
anesthetized by an intraperitoneal injection with pentobarbital (50 mg/kg), and the 
chest was shaved. Animals were intubated with a 20-gauge intravenous catheter, 
ventilated on a rodent respirator (Harvard Apparatus) with a tidal volume of 0.2 
ml at a respiratory rate of 130 breaths/min. The thorax was opened by an 
anterolateral thoracotomy, and ascending aortic constriction (AAC) was 
performed by tying a 7-0 silk suture around the ascending aorta and a 27-gauge 
needle, which was then promptly removed after ligation. The chest was closed 
and mice were allowed to recover on a warming pad until they were fully awake. 
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Sham-operated mice underwent a similar procedure without ligation of the 
ascending aorta. This technique has been shown to provide minimal variability of 
transconstriction pressure gradients in mice. 107  Mice were weighed and 
euthanized 3 weeks after surgery. Total heart and LV with septum were weighed. 
2.11. Echocardiography 
LV dimensions and function were measured in non-anesthetized mice at 3 
weeks after surgery using an Acuson Sequoia C-256 echocardiograph machine 
equipped with a 15-MHz linear transducer (model 15L8). Briefly, the heart was 
imaged in the two-dimensional parasternal short-axis view, and an M-mode 
echocardiogram of the mid-ventricle was recorded at the level of papillary 
muscles. Anterior wall thickness (AWT), posterior wall thickness (PWT), LV 
end-diastolic dimension (EDD) and end-systolic dimension (ESD) were measured 
from the M-mode image. Total wall thickness (TWT) was calculated as AWT + 
PWT. LV fractional shortening (FS) was calculated as (EDD – ESD) / EDD X 
100. 
2.12. Histology 
2.12.1. Hematoxylin and eosin 
LV samples were fixed in 10% buffered formalin, embedded with 
paraffin, and sectioned. To assess myocyte size, sections were stained with 
hematoxylin and eosin and examined by light microscopy (BX 40; 
Olympus). Five random fields from each of four sections per animal were 
analyzed so that 60 myocytes per animal were measured. Myocyte cross-
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sectional area was measured using National Institutes of Health (NIH) 
ImageJ software. To assess fibrosis, sections were stained with Masson’s 
trichrome kit (Sigma) and examined under a light microscope (BX 40; 
Olympus). 
2.12.2. Immunohistochemistry 
Oxidative modifications of SERCA and lipid peroxidation were 
assessed by immonohistochemical staining using site-specific antibodies 
that detect SERCA sulfonic acid at cysteine 674 (Bethyl Laboratories) and 
myocardial 4-hydroxy-2-nonenal (HNE). LV myocardial samples were 
fixed in 10% neutral-buffered formalin, embedded with paraffin, and then 
sectioned (4µm thick). The paraffin sections were then deparaffinated and 
rehydrated in xylene and in decreasing concentrations of ethanol. LV 
tissue sections were blocked with 10% normal goat serum in phosphate-
buffered saline, and subsequently incubated with primary antibody rabbit 
polyclonal anti-SERCA antibody raised against a peptide containing the 
sulfonylated cysteine 674 residue (C674) 5 or mouse anti-4-HNE 
monoclonal antibody, and then incubated with a goat biotin-conjugated 
anti-rabbit secondary antibody or a goat biotin-conjugated anti-mouse IgG 
(Vector Laboratory). The sections were incubated with avidin and 
biotinylated horseradish peroxidase macromolecular complex (Vector 
Laboratory), stained with 3-amino-9-ethylcarbazole as substrate (Vector 
Laboratory) and counterstained with hematoxylin (Vector Laboratory). 
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The samples were examined under a light microscopy (BX 40; Olympus). 
Ten color images of HNE staining were randomly selected from four 
sections of the heart and photographed at a magnification of X40. The area 
and intensity of staining were scored in a blinded manner for 
quantification as follows: 0, no visible staining; 1, faint staining; 2, 
moderate staining; and 3, strong staining. We have previously 
demonstrated the specificity of these antibodies by using blocking 
peptides.  
2.13. BIAM labeling of SERCA 
SERCA-enriched microsomal fractions were incubated in RIPA buffer 
containing 1 mM of biotinylated iodoacetamide (BIAM, Invitrogen) for 1 hour 
at room temperature, and subsequently passed through Zeba™ Spin Desalting 
Columns (7K MWCO, 0.5mL, ThermoScientific) to remove excess BIAM. 100 
µg total protein was incubated with streptavidin-Sepharose beads (GE 
Healthcare) overnight at 4°C. After 3 washes, samples were eluted in Laemmli 
buffer and separated by SDS-PAGE. After transfer to PVDF, membranes were 
blocked and incubated with the mouse monoclonal, anti-SERCA2 (IID8, 
Novus Biologicals) primary antibody and protein-primary antibody complex 
was detected by using infrared-dye conjugated goat anti-mouse polyclonal 
antibody IRDye 680 (Licor), scanned with Licor Odyssey Infrared Imaging 
System.  
		
27 
2.14. Microsome preparation 
Microsomes were isolated from cardiac tissue using a modified cell 
protocol.108 Mouse left ventricles were incubated in a low ionic strength buffer 
(LIS; 10 mM Tris HCL pH 7.5, 0.5 mM MgCl2) with protease inhibitor 
cocktail (PIC) and 0.1 mM PMSF on ice for ten minutes. Tissue was then 
homogenized in a glass 7-mL Dounce homogenizer with a tight “A” pestle for 
40 strokes. An equal volume of Solution A (0.5 M sucrose, 10 mM Tris pH 
7.5, 40 µM CaCl2, 0.3 M KCl) was then added, and homogenized for a further 
20 strokes. Homogenates were centrifuged at 8,000 x g for 20 minutes at 4°C, 
pellets were stored at -80°C for mitochondrial complex activity assays as 
outlined below (2.17), and supernatants were layered over ultracentrifuge tubes 
containing a quarter volume 2.5 M KCl. These supernatants were 
ultracentrifuged at 120,000 x g for 1 hour in a Ti75 rotor at 4°C. Supernatants 
were reserved at -80°C and pellets were resuspended in Solution B (0.25 M 
sucrose, 10 mM Tris pH 7.5, 20 µM CaCl2, 0.15 M KCl) by repeated pipetting 
and vigorous vortexing until particles were no longer visible. Protein 
concentrations were determined by Bradford method and microsomes were 
snap-frozen in liquid nitrogen and stored at -80°C to be used for calcium 
uptake. 
2.15. Maximal calcium uptake 
Maximal calcium-stimulated, thapsigargin-inhibitable SERCA activity 
was measured in microsomal SR preparations from myocardium as previously 
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described,109 with modifications. Briefly, microsomal fractions obtained above 
were pretreated with and without 10 µM of the SERCA inhibitor, thapsigargin 
(Sigma). Calcium uptake was initiated by the addition of 3 mM ATP to 
microsomal membranes preincubated with uptake buffer (120 mM KCl, 25 
mM MOPS, 3 mM MgCl2, 0.5 mM EGTA, 0.45 mM CaCl2, 18 mM potassium 
oxalate, 0.01 mM Ruthenium Red, pH 7.0) containing 1 µCi 45CaCl2 (New 
England Nuclear) in a 37°C heating block. (We used a modified oxalate 
concentration of 18mM to reflect updated protocols detailing the increased 
specificity and prolonged linearity for thapsigargin-sensitive calcium 
sequestering capacity of microsomal vesicles.110) Aliquots of each sample 
taken at 3, 6, and 9 minutes, representing the linear phase of calcium uptake in 
cardiac tissue111 were diluted in ice-cold glass tubes containing quench buffer 
(150 mM KCl, 1 mM LaCl3), immediately vacuum filtered on glass filters 
(Whatman GF/C), washed with quench buffer, placed in vials containing 
scintillation fluid and vortexed for counting with a scintillation counter. 
Remaining aliquots were reserved for total counts. SERCA activity was 
expressed as the initial rate of thapsigargin-sensitive 45Ca2+ uptake in nmol/mg 
protein/min, calculated as (cpm/SA)/mg protein; where cpm = counts per 
minute, and SA = specific radioactivity, calculated as: total counts, in cpm/(µL 
microsomes x 0.45 mM Ca, in nmol). 
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2.16. Mitochondrial complex II activity 
Cardiac mitochondrial fractions were isolated as outlined in 2.14 
Microsome preparation, and complex II activity measured as we have 
previously described.112 All steps were performed at 4 °C. The mitochondrial 
pellet was resuspended in 100–200 µl of HES buffer  (HEPES 5 mM, EDTA 
1 mM, sucrose 0.25 M, pH 7.4 adjusted with KOH 1 M) with 0.2% of BSA 
fatty acid-free. Protein was quantified using BCA (Pierce) and the value of 
HES–BSA buffer alone was subtracted. Complex II enzyme activity of isolated 
mitochondria was measured using a microplate assay kit (Abcam/MitoSciences 
ab109908/MS241). In this assay kit, complex II is immunocaptured within the 
wells of the microplate. The production of ubiquinol by complex II is coupled 
to the reduction of the dye DCPIP (2,6-dichlorophenolindophenol) and a 
decrease in its absorbance at 600 nm is measured spectrophotometrically. The 
assay is performed in the presence of succinate as a substrate. The assay was 
performed in the presence and absence of 5 mM DTT. Enzymatic activity was 
normalized to mitochondrial protein concentration. 
2.17. Peroxynitrite synthesis 
We generated aqueous peroxynitrite as described113 through a synthesis 
reaction of superoxide anion and nitric oxide. We ground 0.3 g potassium 
superoxide with 5g quartz sand in an airtight Erlenmeyer flask under argon gas, 
and perfused with 50 mL nitrogen monoxide gas at a rate of 2 mL/min until the 
sand achieved a pale yellow color. Solid potassium peroxynitrite was recovered 
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by pouring the resultant mixture into 0.01 M potassium hydroxide (ice cold) 
supplemented with manganese dioxide. Sand and MnO2 was filtered off, and 
concentrations were determined by direct UV spectroscopy absorbance at 
302nm. 
2.18. Cameleon imaging 
ARVM cells overexpressing D1ER and 4mtD3cpv adenoviral vectors, 
as described in section 2.2, were imaged using an Olympus IX70 inverted 
epifluorescence microscope fitted with an Olympus DSU spinning disk 
confocal attachement and a Hamamatsu Orca ER cooled CCD camera 
[Olympus 60X 1.4 NA planapochromat oil immersion objective]. The light 
source was a Prior Lumen 220 Pro and dual emission images were acquired 
using a Prior Scientific high-speed filter changer. The filters and dichroic 
mirror where made my Chroma Technologies (ET 436/20X excitation, T455LP 
mirror, and ET 480/40M and ET 535/30M emission filters). Physiological 
temperature (37°C) and 5% CO2 was maintained using a InVivo Scientific 
incubation chamber. Images were acquired using Olympus CellSens software 
and were analyzed using ImageJ (Wayne Rasband, NIH) and the LOCI 
Bioformats plugin (University of Wisconsin-Madison) was used to open the 
Olympus format images. Ratios were calculated as citrine/cpVemission/CFPemission 
after background subtraction and thresholding. Cells were stimulated with 
caffeine (20 mM) and observed for changes in emission ratios. 
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2.19. Statistical analysis 
All data are reported as mean ± SEM. Significance (ANOVA or 
Student’s unpaired t-test) were performed using GraphPad 6 analysis software. 
A P-value < 0.05 was considered to be significant. 
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3. ARVM OVEREXPRESSING REDOX-INSENSITIVE C674S ARE 
RESISTANT TO PRO-HYPERTROPHIC SIGNALING WITH 
PHENYLEPHRINE 
3.1. Rationale 
Growth factors, neuroendocrine signaling,114 ,115 and mechanical strain116,117 
have all been implicated in ROS-dependent and MAPK-dependent pathways of CM 
hypertrophy. 118  It has been well demonstrated that activation of Gαq-coupled 
receptors, particularly αARs, induces MAPK activation through a variety of 
pathways to reactivate transcription of FGP, protein synthesis, and cell growth.119 
The αAR agonists norepinephrine (NE) 120 , 121  and PE, 122  for example, cause 
hypertrophy and fetal gene reactivation in CMs, and are mediated by ROS. αAR-
stimulated hypertrophy by PE was found to be partially dependent on both Ras/Erk123 
and Erk2 activation,124 and NE in the presence of the β-adrenergic receptor (βAR) 
blocker, propranolol, caused early activation of Ras followed by MEK/Erk 
activation, and was associated with MEK1/2- and Erk1/2-dependent protein synthesis 
and FGP transcription. 125  These studies outline a Gαq-mediated role for MAPK 
activation via Ras-Raf-MEK-Erk activation. 
Lower levels of ROS have been implicated in growth signaling126, and small 
concentrations of H2O2 alone can induce protein synthesis in ARVM in an Erk1/2 
dependent manner. 127  Furthermore, αAR-stimulated hypertrophy and MAPK 
activation appears to be ROS-dependent in ARVM,120 likely via NOX.115,121 
Specifically, αAR stimulation induces reversible OPTM of Ras, which was found to 
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be necessary for MEK/Erk activation, protein synthesis and CM hypertrophy. 128  Ras 
contains 4 modifiable cysteine residues,129 and ROS-induced glutathiolation of Ras at 
Cys118 was necessary for propagation of the signal. Expression of TRX, which 
blocks this glutathiolation,130 prevented both MAPK activation and CM growth. 
αAR activation has been shown to increase intracellular calcium in ARVM.131 
Because αAR-mediated hypertrophy requires ROS and is calcium dependent, we 
chose to investigate whether the redox-sensitive enzyme SERCA, which maintains 
calcium stores, plays a role in the transduction of the MAPK signaling pathway. 
Indeed, there is evidence that αAR-stimulation can acutely regulate SERCA at the 
transcriptional level via activation of the calcineurin-NFAT pathway,132 and that 
ROS is required for calcium signaling in CMs generated by shear stress.133 These 
findings support a novel role for SERCA as redox-regulated modulator of αAR-
mediated signaling. 
3.2. Experiments 
3.2.1. 3H-Leucine incorporation 
The hypertrophic response to αAR signaling is characterized by 
increased cell size, associated with up-regulation of fetal gene programs 
necessary for non-proliferative cell growth and elaboration of structural 
proteins. Leucine is an essential amino acid that is required by ARVM for 
protein synthesis. Using radioactive, tritiated leucine we calculated the 
amount of [3H]leucine uptake into ARVM in the presence of an αAR 
agonist. This amino acid incorporation serves as a surrogate measure for 
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protein synthesis by the cell. ARVM infected with WT SERCA, C674S 
SERCA, or lacZ control adenoviruses for 16 hours were treated with 
phenylephrine (PE, 10uM) over a further 36 hour period. PE increased 
leucine incorporation in both lacZ control (67 ± 3%, p < 0.01) and WT 
SERCA-expressing ARVM (58 ± 14%, p < 0.01), but caused no 
significant increase in leucine incorporation in C674S-infected cells, 
which had significantly decreased uptake (72 ± 17%, p < 0.001) compared 
to ARVM overexpressing a comparable amount of WT SERCA (n = 4). 
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Figure 2. C674 is required for phenylephrine-induced protein synthesis. 
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3.2.2. MAPK signaling cascade 
αAR-induced hypertrophy is mediated predominantly by MAPK 
activation.125 MAPK signaling is canonically activated in a relatively 
linear fashion of Ras-Raf-MEK-Erk, where activation of Ras stimulates 
Raf isoforms, which activates MEK, which activates Erk, which initiates 
transcription programs responsible for growth signaling. Phosphorylation 
of each protein in the pathway is therefore a measure of its upstream 
regulatory kinase’s activity, e.g. Erk phosphorylation is a direct correlate 
of MEK activity. 
3.2.2.1. Erk 
As such, Erk1/2 (p42/44 MAPK) phosphorylation  
indicates MEK activation, which phosphorylates its only known 
target, Erk, at its Thr202/Tyr204 sites when activated (see Table 
1). This phosphorylation of Erk is the signal which goes on to 
activate a number of downstream cytosolic and nuclear 
transcription factors, including Elk-1, ribosomal protein p90S6K, 
and c-myc, which are all involved in cellular growth pathways in 
CM hypertrophy.134 PE (5 min) induces a robust Erk response in 
ARVM characterized by increased Erk phosphorylation in both 
lacZ controls (10.2 ± 1.4-fold, p < 0.0001) and WT SERCA-
expressing ARVM (10.0 ± 1.2-fold, p < 0.0001) accounting for 
significant αAR-inducible MEK activity. ARVM expressing 
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C674S SERCA had a blunted response compared to ARVM 
expressing WT SERCA (5.4 ± 0.7-fold, p < 0.01), which 
represented a significant decrease in αAR-stimulated Erk 
phosphorylation (36 ± 13%, p < 0.05) compared to WT (n = 4).  
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Figure 3. C674 contributes to phenylephrine-induced MAPK activation. 
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3.2.2.1.1. Role of complete vs. partial αAR agonist with βAR activity 
Although phenylephrine has been used extensively in 
CM literature to demonstrate a hypertrophic response to αAR 
stimulation, its pharmacological action is a partial αAR agonist 
and may have βAR-mediated effects at increased 
concentrations. Concurrent stimulation of βAR, while also a 
potent activator of SERCA via dephosphorylation of PLN, is 
known to alter PKA/Akt-dependent phosphatases, which 
regulate the MAPK pathway. In ARVM, βAR stimulation has 
been shown to attenuate αAR-induced protein synthesis, for 
example.135 Conversely, βAR blockade has been observed to 
increase the FGP response in PO.136 To determine whether the 
MAPK response we observed was relevant to pure αAR 
activation or merely specific to a combined, α/βAR effect of PE 
signaling, we compared MAPK activation in ARVM treated 
with PE (10uM, 5 min) to ARVM treated with the NE (1 µM, 5 
min) in the presence of the βAR blocker propranolol (2uM, 30 
min pretreatment). We found that both stimuli induced Erk 
phosphorylation as described in 3.2.2.1, but found no difference 
in Erk activation between PE and NE + propranolol groups, in 
either WT or C674S mutant ARVM (n = 3).  
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Figure 4. Phenylephrine-induced MAPK activation is unaffected by βAR blockade. 
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3.2.2.2. MEK 
MEK1/2 phosphorylation is a measure of Raf activity, which 
phosphorylates MEK at its Ser217/221 sites when activated (See 
Table 1). Phosphorylation of MEK is the signal that goes on to 
activate Erk, its only known target. PE (5 min) increased MEK 
phosphorylation in both LacZ controls (5.3 ± 1.0-fold, p < 0.001) and 
WT SERCA-expressing ARVM (4.6 ± 1.1-fold, p < 0.01), ostensibly 
due to αAR-induced Raf activation. Unlike Erk, MEK 
phosphorylation was not significantly increased in ARVM expressing 
C674S after PE treatment, though the mean trended upward (2.0 ± 
0.3-fold, p = ns) compared to baseline. Regardless, this difference 
accounted for a significantly decreased MEK response to αAR 
stimulation (58 ± 19%, p < 0.05) compared to WT (n = 6). 
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Figure 5. C674 is required for Raf activation of MEK. 
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3.2.2.3. Raf 
Raf signaling is comparably complex and has several target 
sites of phosphorylation activated by various signaling pathways. Raf 
is phosphorylated by regulatory kinases, like Ras, as well as its 
downstream effector molecules in a mode of feedback regulation. 
Although these sites have varying effects on Raf activity, all are 
phosphorylated by activation of the MAPK cascade and indicate 
activation of this pathway. 
3.2.2.3.1. S289/296/301 
Raf S289/296/301 are recently identified regulatory 
phosphorylation sites which are dependent upon both 
endogenous Erk-1 activity and MEK signaling. Raf activation is 
sustained by this Erk-dependent phosphorylation, which 
represents a positive-feedback loop, with Raf regulated by its 
downstream effectors, MEK and Erk, and prevented with the 
MEK inhibitor, U0126.137 Raf S289/296/301 phosphorylation is 
therefore a measure of Erk activation, and would be expected to 
be stimulated by αAR. Indeed, PE (5 min) increased Raf 
phosphorylation at these sites in both lacZ controls (3.5 ± 0.3-
fold, p < 0.0001) and WT SERCA-expressing ARVM (3.2 ± 
0.4-fold, p < 0.0001), in line with Erk data.  Raf S289/296/301 
phosphorylation is not significantly increased in ARVM 
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expressing C674S with stimulation by PE (1.6 ± 0.2 fold, p = 
ns), which is significantly decreased (48 ± 10%, p < 0.001) 
compared to WT (n = 4). Combined with the decrease in MAPK 
activation observed in 3.2.2.1, these data confirm that decreased 
Erk phosphorylation also decreases the regulatory feedback 
effect on Raf. 
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Figure 6. C674 is required for Erk-dependent feedback potentiation of Raf. 
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3.2.2.3.2. S259 
Phosphorylation of Raf S259 also regulates Raf activity. 
While this site is recognized to be inhibitory, it is also a measure 
of MAPK activation, though in a manner consistent with 
negative feedback. Raf S259 phosphorylation is mediated by 
action of either PKA138 or Akt,139 and therefore may represent 
βAR-dependent inhibition by PE. Regardless, it is likely that 
S259 phosphorylation contributes to the hyperphosphorylation 
of Raf, which occurs with prolonged stimulation, rendering the 
enzyme inactive.140 Raf S259 is also a substrate of the protein 
phosphatase PP2A, which dephosphorylates Raf and is sensitive 
to changes in [Ca2+]i. Raf S259 phosphorylation is similarly 
increased with PE (5 min) in both lacZ control (2.3-fold) and 
WT SERCA-expressing ARVM (1.9-fold). The increase in Raf 
S259 phosphorylation in ARVM expressing C674S SERCA is 
correspondingly blunted (1.3-fold), representing a decrease 
(33%) in S259 phosphorylation in the C674S mutant. These 
data indicate that negative feedback inhibition is regulated by 
C674 as well (n = 1). 
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Figure 7. C674 is required for PE-induced feedback inhibition of Raf. 
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3.2.2.3.3. S338 
Phosphorylation of the S338 moiety on Raf is directly 
mediated by its upstream kinase Ras. It is the main site thought 
to be responsible for Ras-dependent Raf activation at the plasma 
membrane,141 and Raf S338 phosphorylation in mouse hearts in 
vivo is up-regulated with pressure-overload induced 
hypertrophy.142  S338 phosphorylation is therefore a reliable 
measure of Ras activity. In line with previous data showing 
SERCA C674-regulated MAPK activation with αAR 
stimulation, we tested Ras-dependent phosphorylation of Raf. 
As before, PE (5 min) induced comparable increases in Raf 
S338 phosphorylation in lacZ control (3.9 ± 0.4-fold, p < 0.001) 
and WT SERCA-expressing ARVM (3.5 ± 0.6-fold, p < 0.001). 
Interestingly, ARVM overexpressing C674S mutant SERCA 
also had a comparable increase in Ras-dependent Raf activation 
(3.8 ± 0.5-fold, p < 0.001), with no significant differences 
between groups (n = 3). These data suggest that Raf is not 
differentially activated by Ras even in the presence of redox-
insensitive SERCA.  
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Figure 8. C674 does not modulate PE-mediated Ras activation of Raf. 
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3.2.2.3.4. Ras activity 
In order to confirm the novel finding that Ras-dependent 
Raf activation was independent of SERCA as indicated by Raf 
S338 phosphorylation, we employed a direct measure of Ras 
activity via a Raf pull-down assay. Active RasGTPase binds to 
Raf to initiate its signaling cascade, and we tested if Ras-Raf 
binding was also unaffected by C674S expression. In agreement 
with our previous results, PE (5 min) stimulated increases in 
Ras activity in lacZ control (35 ± 6%, p < 0.01), WT SERCA 
(31 ± 1%, p < 0.01), and C674S SERCA-expressing ARVM (34 
± 7%, p < 0.01), with no significant differences between groups 
(n = 4). These data confirm that Ras activity is not dependent on 
SERCA regulation by C674. 
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Figure 9. αAR-stimulated Ras activation is SERCA C674-independent. 
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3.2.2.3.5. PP2A activity 
Given the results of the Raf Ser259 study, to investigate 
the regulation of the MAPK cascade downstream of Raf 
activation, we chose to test the activity of the calcium-sensitive 
protein phosphatase, PP2A. PP2A is known to dephosphorylate 
both Raf and MEK, and has been implicated in the Erk-
dependent pathway of cardiac hypertrophy. 143  By 
dephosphorylating Raf, PP2A may interrupt Ras-dependent 
activation, or conversely reset the protein by removing the 
inhibitory effects of hyperphoshorylation and make it once 
again available for signaling. 144 PP2A is calcium sensitive,145 
and its activity has been reported to be regulated by changes in 
intracellular [Ca2+] in cardiac progenitor cells.146 Because PP2A 
acts on the MAPK pathway below the level of Ras, we tested 
PP2A activity in our system to assess how uninterrupted 
activation of Ras by αAR-signaling is modulated downstream 
by redox regulation of SERCA, and by extension [Ca2+]i. PE (5 
min) induced no changes in PP2A activity as measured by 
generation of inorganic phosphates from phosphorylated 
substrates in either lacZ control or WT SERCA-expressing 
ARVM, which were unchanged at baseline. However, ARVM 
expressing C674S SERCA had significantly increased PP2A 
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activity after αAR stimulation (75 ± 24%, p < 0.05, n = 3). 
These data indicate that SERCA C674 downregulates PE-
mediated activation of PP2A. 
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Figure 10. C674 downregulates PE-mediated PP2A activation. 
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3.2.3. Reversible modifications of SERCA 
CM hypertrophic events as evaluated by protein synthesis and 
MAPK signaling were drastically altered in ARVM by the single amino-
acid substitution of C674S on SERCA. Elimination of this redox-sensitive 
site seems to be crucial in regulating growth pathways in αAR-mediated 
hypertrophic signaling. Because ROS are known to mediate Gαq-induced 
hypertrophy, and redox regulation of C674 has repeatedly been shown to 
alter SERCA function, we hypothesized that PE induced an OPTM of 
SERCA at C674. We further hypothesized that the OPTM induced by PE 
would be reversible, consistent with a role for C674 as a redox switch on 
SERCA responsible for regulating PP2A. We assessed reversible OPTM 
of SERCA using a biotin switch assay. Using this method, any increase in 
BIAM-bound SERCA is directly attributable to an increase in reversible 
modifications of SERCA when normalized to total protein. We found that 
treatment with PE (5 min) induced a doubling in reversible SERCA 
OPTM (2.0 ± 0.2-fold, p < 0.01), which did not occur in the C674S mutant 
(0.8 ± 0.2-fold, p =  ns), representing a significant decrease (60 ± 11%, p < 
0.001) in αAR-inducible OPTM of SERCA in the redox-insensitive 
mutant (n = 4). Furthermore, reversible OPTM of SERCA at baseline were 
not altered in the mutant, indicating that C674 is the site responsible for 
virtually all of the OPTM occurring with αAR stimulation.  
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Figure 11. αAR activation induces a reversible OPTM at C674. 
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3.3. Discussion 
3.3.1. Decreased growth with C674S expression 
The diminished [3H]leucine incorporation seen in ARVM with 
expression of C674S SERCA indicates that SERCA plays a critical role in 
mediating the hypertrophic response to αAR stimulation. ROS is known to 
be required for αAR-mediated hypertrophy, and the traditional MAPK 
signaling pathway leading to this activation is regulated by calcium. This 
experiment shows for the first time that redox-mediated alterations in 
SERCA function due to αAR signaling are required for the CM growth 
response. 
3.3.2. SERCA modulation of PP2A activity and MAPK signaling 
As hypertrophy is decreased in C674S SERCA-expressing ARVM, 
we hypothesized that downregulation of signaling in the MAPK pathway 
was interrupted via a calcium-mediated effector. We identified that 
expression of redox-insensitive SERCA interrupts the MAPK cascade at 
the level of Raf, as Ras activation by PE was unaltered, but downstream 
Raf and MEK activity were decreased. Ras-mediated MAPK activation 
has been described in the ER of Cos-1 and HeLa cells,147,148 and Raf 
activation has been shown to be both Ras- and calcium-dependent in HeLa 
cells.149  Because Raf activation was unaltered, we proposed a role for 
PP2A in mediating this modulation downstream of Ras, as it is known to 
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dephosphorylate the MAPK cascade at the levels of Raf and MEK, 
consistent with our data. Because PP2A is calcium-activated, this 
elucidates a mechanism for how modified SERCA may regulate this 
pathway. In the course of these experiments we also dissociated the 
paradoxical effects observed between αAR and βAR stimulation to show 
that the alterations we observed with C674S-SERCA were truly αAR-
dependent. 
3.3.3. Reversible OPTM of SERCA at C674 with αAR activation 
Activity of the calcium-sensitive PP2A is altered by C674S 
expression. Inhibiting αAR-mediated OPTM of SERCA C674 appears to 
be permissive of PP2A activity. As SERCA activity is known to be 
regulated by OPTM at C674 in ARVM, we hypothesize that introduction 
of a reversible SERCA modification at this site by PE would increase 
SERCA activity and reduce [Ca2+]i., explaining the lack of PP2A 
activation. This decrease in PP2A activity is dependent on the redox-
availability of SERCA C674 with αAR, and preventing this modification 
up-regulates its activity and decreases MAPK signal transduction.  This 
modification is consistent with αAR-induced OPTM of Ras thiols, 
indicating a likely role for redox-mediated SERCA regulation of the 
MAPK pathway. 
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3.3.4. Conclusion 
Our experiments in ARVM show a clear link between SERCA 
oxidation and hypertrophic signaling. Reversible OPTM of SERCA C674 
is associated with increased SERCA activity in ARVM. As MAPK 
signaling and phenotypic hypertrophy is significantly inhibited by 
expression of the redox insensitive C674S, OPTM of C674, mediating 
increases in SERCA function is the likely regulator of MAPK signaling 
via inhibition of the calcium-activated PP2A. Decreased PP2A activity via 
redox-activated SERCA potentiates MAPK signaling and hypertrophy, as 
evidenced by increased PP2A activity in ARVM expressing redox-
insensitive SERCA. This increased PP2A activity interrupts transduction 
of the MAPK cascade and protein synthesis in the mutant, attenuating the 
hypertrophic response.  
C674S expression did not completely inhibit the Erk response to 
αAR activation, indicating that Ras-mediated activation of Erk was still 
present despite significant downregulation by redox-insensitive SERCA. 
This indicates that redox activation of SERCA strongly modulates CM 
hypertrophy by suppressing PP2A activation induced by αAR signaling. 
When this mechanism is interrupted, PP2A cannot be appropriately down 
regulated and begins to turn off the normal hypertrophic signaling 
response. 
  
		
60 
Figure 12. SERCA-dependent MAPK regulation by PP2A below Ras 
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4. MYOCYTES ISOLATED FROM SKI MICE IN VITRO HAVE ALTERED 
SERCA FUNCTION AND HYPERTROPHIC SIGNALING RESPONSE 
4.1. Rationale 
Adult mouse myocytes are famously difficult to culture for extended 
periods in vitro and have rarely been utilized to study signaling pathways in the 
literature. However, we wanted to confirm our findings from the reductionist, 
overexpression model in ARVM was in myocytes isolated from transgenic SKI 
mice. While αAR-dependent Erk activation is observed in AMVM,33, 150 
adrenergic pathways are divergent between mouse and rat models and a clear 
linkage to hypertrophy using this stimulus in AMVM has not been 
demonstrated.151 Using a modified isolation protocol described above, we were 
able to culture adult mouse myocytes for 24 hours, sufficient time for cells to 
adjust to in vitro conditions for signaling experiments, as well as freshly isolate 
CMs for determination of SERCA function via contractility experiments. We 
used these experiments to confirm our findings regarding C674S effects on 
signaling in ARVM and elucidate the effect of C674 on altered SERCA function 
in the mouse model. These studies will also serve as a bridge to demonstrate the 
relevance of the in vitro experiments in ARVM to our in vivo model of pressure 
overload outlined in chapter 5. 
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4.2. Experiments 
4.2.1. MAPK signaling in AMVM 
Consistent with our findings in ARVM, myocytes from SKI mice 
have a diminished response to αAR stimulation. While mouse myocytes 
may use alternate pathways to stimulate cardiomyocyte hypertrophy,152 PE 
treatment (15 min) has been described to induce significant activation of 
Erk1.104 Although the MAPK response was not as robust as ARVM, there 
was a significant increase in MAPK activation with αAR stimulation with 
NE (1 µM, 15 min) and propranolol (2 µM, 30 min pretreatment) in WT 
CMs (51 ± 22%, p < 0.05). Moreover, in mouse myocytes, C674S 
mutation in only 50% of SERCA was sufficient to completely eliminate 
the MAPK response (9 ± 1%, p = ns) compared to baseline (n=7). These 
data suggest that C674S plays a similar role in transduction of MAPK 
signals in the mouse myocyte, demonstrating generalizability of the 
mechanism outlined above to our mouse model. 
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Figure 13. SKI myocytes are not susceptible to MAPK activation via αAR signaling. 
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4.2.2. Alternate signaling pathways 
While MAPK signaling is a robust response to αAR activation, it is 
by no means the only prohypertrophic signaling pathway that is both 
calcium-dependent and ROS-regulated in CM. We investigated other 
major pathways that have been described to be important in Gαq-mediated 
hypertrophy models and in ARVM, including PKC and CAMKII. The 
phosphatase calcineurin, activated by the [Ca2+]i/calmodulin complex, 
may also regulate MAPK-dependent hypertrophy.153 While In neonatal rat 
cardiac myocytes (NRCM)154,155 and transgenic models156,157 calcineurin 
activation is implicated in FGP and Gαq -mediated hypertrophy, a role in 
ARVM hypertrophy is not observed.158 We therefore chose to focus on 
PKC and CAMKII pathways, which may be activated in both mouse and 
rat models of αAR stimulation. 
4.2.2.1. PKCalpha 
PKCα is a member of the classical PKC isoforms which are 
activated in CM in a PLC-dependent manner, via the combined 
actions of DAG and IP3R-derived [Ca2+]i. Upon activation, PKC is 
recruited to the membrane, and can activate MAPK via Raf, 
persisting beyond dissipation of the [Ca2+]i stimulus. In rat models of 
hypertension the PLC-dependent classical PKC isoforms, PKCα, 
PKCβ, and the calcium-independent novel isoform PKCδ  have all 
been linked to the development of cardiac hypertrophy, while the 
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atypical PLC-independent isoform PKCε is thought to regulate 
physiological hypertrophy and cardioprotection.159 Thus, we chose to 
investigate the effects of SERCA on αAR-dependent activation of 
the calcium-sensitive, prohypertrophic PKCα isoform, which is 
abundant in cardiac tissue. The role of PKC has been particularly 
difficult to identify in regards to modulation by SERCA, partly due 
to classic inhibitors like chelerythrine exerting nonspecific toxicity 
on SERCA.160 Using our αAR stimulus which activated MAPK in 
WT AMVM, we found no significant increase in PKCα activation as 
measured by phosphorylation, nor did we see any baseline 
differences in PKCα phosphorylation between WT and SKI 
myocytes, either before or after αAR stimulation (n = 3). Indeed, 
data from one group simultaneously found that while PKCα was 
shown to be integral to Erk signaling and hypertrophy in NRCM, 161 
PKCα KO did not protect mice from PO-induced hypertrophy.162 
These findings confirm that PKCα signaling in mouse CM is not 
regulated by SERCA.  
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Figure 14. PKCα activation is αAR-independent in CM from WT and SKI mice. 
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4.2.2.2. CAMKII 
CAMKII is also calcium-dependent and its activation has 
been implicated in cardiac hypertrophy,163,164 and more recently has 
been found to be constitutively activated by redox signaling.165 
While CAMKIIδ specific KO may have a protective effect on PO-
induced hypertrophy,166 conflicting studies from total CAMKII KO 
mice conducted in parallel had no effect on PO-induced hypertrophy, 
cell size, or FGP, though did delay transition to failure.167 CAMKII 
activation is mediated by binding of the  [Ca2+]/calmodulin complex 
which induces autophosphorylation at Thr286 and continues to 
activate the enzyme after the calcium stimulus is removed.168 β1AR 
stimulation in parallel with, or upstream of PKA activation induces 
this calcium-dependent CAMKII autophosphorylation, 169  which 
increases SERCA2a activity by phosphorylating its inhibitor, 
PLN.170 As with PKCα, CAMKII activation as measured by Thr286 
phosphorylation of all three CAMKIIβγδ isoforms (CAMKIIδ being 
the most prevalent in CM) was not regulated by our αAR stimulus. 
Similarly, no baseline differences were observed between SKI and 
WT myocytes either before or after stimulation, confirming that 
baseline CAMKII activation is also not SERCA-dependent (n = 3).  
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Figure 15. CAMKIIβγδ activation is αAR-independent in WT and SKI CM. 
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4.2.3. Baseline SERCA function in AMVM 
Surprisingly, contractile analysis of isolated ventricular myocytes 
from adult SKI mice show decreases in baseline SERCA function 
compared to WT AMVM. Although SKI mice lack an outward cardiac 
phenotype in the absence of pathological stressors, we hypothesized that 
altering C674 SERCA may be sufficient to affect calcium handling. As 
reversible thiol modifications exist in equilibrium much like 
phosphorylation, we suspect that some population of SERCA will be 
variably modified at baseline. Decreased SERCA-mediated calcium 
uptake and ER stores were observed in endothelial cells from SKI animals, 
and C674 has been shown to be necessary for the EC growth signaling 
response.106 Experiments conducted on AMVM stimulated to contract 
under physiological conditions (5Hz, 37°C) showed that the exponential 
time constant of calcium reuptake (τ), which is a direct correlate of 
SERCA activity, is decreased in SKI myocytes (20 ± 7%, p < 0.05). 
Interestingly, this downregluation of calcium decay was not associated 
with an increase in diastolic calcium (8 ± 6%, p = ns), suggesting that the 
slowed rate of calcium uptake does not represent an inability of SERCA to 
clear calcium in diastole. It does however reflect a decrease in the overall 
calcium transient (17 ± 6%, p < 0.05), supported by a trend to increased 
time to peak systolic calcium (14 ± 8%, p = 0.14) and a significant 
decrease in sarcomere shortening (35 ± 9%, p < 0.05). Sarcomere length is 
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unchanged in SKI myocytes, indicating no gross changes in myocyte 
structure accounting for the altered contractile properties (2 ± 1%, p = ns; 
n = 3 for all experiments, 9-11 myocytes analyzed per animal). Taken 
together, these data suggest that SERCA function is diminished at baseline 
by replacement of C674 with a redox-insensitive serine and may interfere 
with contractility, but does not appear to significantly alter the relaxation 
capacity of the cell. 
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Figure 16. SERCA-mediated calcium reuptake is slowed in SKI myocytes. 
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Figure 17. Diastolic calcium levels are preserved in SKI myocytes.  
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Figure 18. C674S expression reduces calcium transient amplitudes. 
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Figure 19. C674S expression may slow calcium-dependent contraction. 
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Figure 20. C674 is required for maintaining baseline myocyte contractility. 
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Figure 21. C674S expression does not alter sarcomere structure. 
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4.3. Discussion 
4.3.1. Calcium-sensitive hypertrophic signaling pathways 
Our goal in using SKI myocytes for short-term signaling 
experiments was to confirm our findings in ARVM and determine if the 
mechanism outlined above had relevance to our transgenic model. MAPK 
signaling is activated in AMVM using a comparable stimulus, and 
similarly prevented by SKI. In fact, the degree of inhibition was even 
greater in the mouse model, which only accounts for 50% altered SERCA. 
We also chose to investigate alternative pathways for hypertrophic 
signaling to determine if αAR-stimulation was mediated by other 
pathways in the mouse, and found that two major calcium-sensitive 
mediators of hypertrophy were not activated by our αAR agonist, nor 
impacted by C674S expression.	
4.3.2. Significance of C674 on SERCA activity 
Excitation-contraction coupling (ECC) describes the process 
whereby a calcium stimulus is transduced to a contractile response in CM. 
Membrane depolarization initiates extracellular calcium carried in t-
tubules to enter the CM via the sarcolemmal L-type calcium channels 
(LTCC), causing local rises in [Ca2+]i. This signal activates ryanodine 
receptors (RyR) on the SR membrane to dump cellular stores via a 
calcium-induced calcium release mechanism. The resultant spike in [Ca2+]i 
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binds troponin C (TnC), which displaces tropomyosin (Tm) from the 
myofilament and facilitates breaking and reforming of myosin-actin 
crossbridges, causing the cell to contract. The action of SERCA serves to 
regulate two main parameters of CM contractility: relaxation, and calcium 
stores. By pumping calcium ions out of the cytosol and back into the SR, 
SERCA is responsible for the relaxation phase of the contraction cycle. 
This is observed experimentally in models of diastolic heart failure, where 
SERCA levels and function are decreased and contribute to diastolic 
dysfunction associated with impaired relaxation. In addition, as a primary 
determinant of [Ca2+] available in the SR, SERCA can modulate systolic 
function as well, which is dependent upon the speed and amplitude of the 
calcium transient. Dysregulation of SERCA function can therefore impair 
relaxation as well as contraction, and both of these parameters appear to 
be altered in isolated SKI myocytes. Modifying this single redox-sensitive 
site is therefore critical to SERCA function, which may require basal 
OPTM at C674 for unstimulated activity. 
4.3.3. Conclusion 
As SKI completely blocked MAPK signaling in the mouse 
myocytes and other signaling pathways were neither stimulated nor 
affected by SKI, we concluded that redox-activated SERCA plays a 
significant role in hypertrophic signaling in the mouse myocyte through 
the MAPK cascade, and attribute the mechanism described in ARVM as 
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an appropriate model for these changes. We further concluded that 
alternate hypertrophic pathways are likely unaffected by αAR stimulation, 
and not the mechanism of action by which redox-sensitive SERCA exerts 
its prohypertrophic effects. 
We were also interested to find that baseline SERCA activity was 
altered in SKI myocytes. This suggests an important role for redox 
signaling in the regulation of contractile function. One possibility is that 
SERCA C674 is redox-activated under basal conditions, and C674S 
mutation prevents this activation, leading to fundamental differences in 
calcium handling, even before stimulation with hypertrophic signaling. 
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5. SKI MICE ARE PROTECTED FROM EARLY CHANGES IN CHRONIC 
PRESSURE OVERLOAD 
5.1. Rationale 
Chronic pressure overload is a widely-studied model of hypertension, and 
has been used to implicate a number of important signaling pathways in 
mediating the cardiac remodeling associated with heart failure. While few 
models specifically examine the effects of PO early in the pathogenesis of 
disease, almost all show an initial increase in cardiac size associated with a 
compensatory preservation of ejection fraction (EF). It is thought that this 
hypertrophy is an adaptive response to increased cardiac afterload and a reactive 
mechanism to mitigate increasing wall stress. Though models of PO inevitably 
decompensate and progress to dilated heart failure with decreased EF over time, 
the initial remodeling does not definitively presuppose failure, and preventing 
hypertrophy has been shown to both prevent and accelerate failure in the various 
models outlined in section 1.2. This suggests that unique signaling pathways may 
exist which regulate cardioprotection acutely, and are distinct from those which 
cause chronic adverse remodeling. Published data from our laboratory suggests 
that LVH at 3-weeks of PO is preventable with transgenic overexpression of the 
anti-oxidant catalase (pCAT), which also attenuates congestive heart failure 
(CHF) at 12-weeks. Though the mechanism is not known, SERCA was observed 
to be oxidized at C674 in this model, which was prevented by pCAT.48 Due to 
our findings in both ARVM and AMVM in vitro that short-term hypertrophic 
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stimulation regulates CM growth, hypertrophic signaling pathways, and SERCA 
oxidation in a C674-dependent manner, we hypothesized that preventing C674 
oxidation of SERCA in an in vivo model of Gαq-mediated hypertrophy, chronic 
pressure overload, would attenuate LVH by the mechanism elucidated in chapter 
3. Furthermore, because SERCA C674S-homozygote mice die in utero at the 
stage of cardiac development, it is likely this site is an important regulatory 
switch permissive of CM growth in both development and PO-mediated 
induction of the FGP. 
5.2. Experiments 
5.2.1. PO-induced LVH in SKI mice 
We assessed various parameters of cardiac remodeling to study the 
effects of SERCA C674 on LVH induced by 3 weeks of PO via AAC. WT 
hearts had significantly increased heart:body weight (HW:BW) ratios (50 
± 10%, p < 0.01) with AAC. Hearts from SKI animals also had increased   
HW:BW (34 ± 10%, p < 0.01), but had significantly attenuated 
hypertrophy (32 ± 6%, p < 0.05) compared to WT AAC. This increase in 
myocardial mass correlated with hypertrophy of the LV, as measured by 
echocardiography to determine total wall thickness (TWT). AAC induced 
a rise in both WT (24 ± 4%, p < 0.001) and SKI (13 ± 2%, p < 0.01) LV 
wall thickness, but LVH was partially protected in SKI (44 ± 2%, p < 
0.05) vs. WT AAC. We also analyzed individual myocyte size via 
histology to assess what proportion of LVH was due to CM growth. CM 
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diameter was significantly increased by AAC in WT hearts (70 ± 17%, p < 
0.01), but not in CM from SKI hearts (8 ± 6%, p = ns). This represents 
significant inhibition of CM growth in SKI hearts (37 ± 10%, p < 0.05) 
compared to WT with AAC. Cardiac remodeling in hypertrophy is also 
characterized by fibroblastic elaboration of interstitial layers of collagen, 
resulting in increased wall thickness and stiffness as LVH progresses. 
Although we did not expect fibrosis to be up markedly early in this model, 
we wanted to know if contributions from non-myocyte growth were 
attributable to the increases in heart weight and wall thickness. Although 
no significant differences were observed, fibrosis may be mildly elevated 
in WT hearts with AAC (2.3 ± 0.7%) vs sham (0.6 ± 0.1%) p = ns, and in 
SKI AAC (1.6 ± 0.5%) vs. sham (0.6 ± 0.1%) p = ns. No significant 
changes were observed between groups, indicating that fibrosis is not 
upregulated early in the course of AAC and SKI does not contribute to this 
phenotype by 3 weeks. These data (n = 6-14) support the hypothesis that 
PO-induced hypertrophy is mediated by C674-dependent growth in the 
CM.  
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Figure 22. SKI mice are protected from AAC-associated cardiac enlargement. 
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Figure 23. SKI mice are protected from AAC-associated LVH. 
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Figure 24. C674 is required for AAC-mediated CM growth. 
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Figure 25. AAC-mediated cardiac fibrosis is not regulated by C674. 
W
T  
s h
am
S K
I s
h a
m
W
T  
A A
C
S K
I A
A C
0
1
2
3
4
C
a
rd
ia
c
 f
ib
ro
s
is
(%
)
n s
 
  
		
87 
5.2.2. Systolic function following 3 week-PO 
Pressure overload is a commonly used model for inducing cardiac 
hypertrophy. However, chronic or severe pressure overload typically 
progresses to a heart failure phenotype characterized by either diastolic 
failure with relaxation abnormalities but preserved EF, or decompensated 
systolic failure typified by chamber dilation and decreased EF on 
echocardiogram. We studied the initial stages of cardiac hypertrophy early 
in the model to examine the effects of redox signaling on CM growth 
before cardiac dysfunction was manifest. We found that while hypertrophy 
was present at 3 weeks, measures of chamber dilation and systolic 
dysfunction were not pronounced at this stage, as measured by end 
diastolic dimension (EDD), end systolic dimension (ESD), and fractional 
shortening (FS, a surrogate for EF), represented in Table 2. Heart rate 
(HR), total heart weight (THW), and body weight (BW) were also 
obtained and are provided as a reference.  
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Table 2. Diastolic dysfunction is not present in mice subjected to AAC at 3 weeks. 
 WT sham 
(n = 6) 
SKI sham 
(n = 7) 
WT AAC 
(n = 14) 
SKI AAC 
(n = 10) 
EDD (mm) 2.95 ± 0.03 2.90 ± 0.06 3.09 ± 0.11 3.03 ± 0.03 
ESD (mm) 1.17 ± 0.02 1.17 ± 0.03 1.40 ± 0.14 1.22 ± 0.02 
FS (%) 59.9 ± 0.3 60.4 ± 0.3 55.2 ± 2.5 59.9 ± 0.4 
HR (bpm) 710 ± 14 657 ± 20 689 ± 11 673 ± 9 
HW (mg) 130 ± 11 138 ± 9 201 ± 13** 165 ± 11 
BW (g) 26.2 ± 1.9 28.8 ± 2.4 23.8 ± 2.4 26.7 ± 4.0 
**p < 0.01 vs. WT sham  
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5.2.3. Global oxidative stress following 3 week-PO 
Similar to diastolic dysfunction, severe and chronic models of 
pressure overload are associated with increased oxidative stress and 
irreversible protein OPTM, lipid peroxidation, and protein degradation. As 
we propose a signaling role for redox activation of SERCA, we wanted to 
confirm that nonspecific, global levels of oxidative stress were not 
increased at this time point, which would preclude this hypothesis. 
5.2.3.1. Mitochondrial complex II activity 
Increased oxidative stress from oxidant generators such as 
NOX, NOS, or mitochondria are thought to mediate pathophysiology 
in PO models. We tested mitochondrial complex II activity, which 
our laboratory has shown to be susceptible to both reversible and 
irreversible OPTM. Our results indicate that enzyme activity as 
measured by complex II-specific reduction of an optically sensitive 
substrate is decreased by oxidative stress in AAC-challenged WT 
mice (26 ± 10%, p < 0.05) compared to shams. SKI mice are 
resistant to this downregulation by AAC (3 ± 8%, p + ns), and have 
significantly higher complex II activity (21 ± 6%, p < 0.01) than WT 
AAC. While complex II appears to be modified by oxidative stress 
produced in pressure overload, we also wanted to test whether this 
OPTM was reversible. Using the reducing agent DTT, we found that 
this AAC-mediated decrease in activity was completely reversible, 
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and DTT significantly increased complex II activity in WT AAC 
mice (24 ± 5%, p < 0.05) back to baseline levels (n = 5). These data 
suggest that while PO induces oxidative stress sufficient to regulate 
enzymatic function at 3 weeks, it does so via a reversible 
mechanism. 
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Figure 26. Mitochondrial complex II activity is downregulated by AAC-induced 
oxidative stress. 
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Figure 27. AAC-mediated complex II OPTM is reversible at 3 weeks. 
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5.2.3.2. Formation of irreversible HNE adducts 
While reversible redox signaling can activate SERCA, severe 
oxidative stress is also known to irreversibly sulfonylate C674 and 
inhibit its function. We wanted to measure global oxidative stress in 
the early stages of PO to determine whether the severe oxidative 
phenotype observed in advanced stages of heart failure was present.  
We performed immunohistochemical staining with an antibody 
directed against 4-hydroxy-2-nonenal (HNE) to evaluate the 
myocardium for the presence of lipid peroxidation. Histological 
analysis showed no differences in HNE adducts between WT sham, 
SKI sham, WT AAC, and SKI AAC groups (n = 3).  These data 
show that while oxidative modifications are present in the early 
stages of PO and may regulate enzymatic function, the severe 
oxidative stress associated with irreversible oxidation late in the PO 
model does not appear to be present at 3 weeks.  
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Figure 28. PO is not associated with irreversible lipid peroxidation at 3 weeks.  
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5.2.4. AAC-induced modifications of SERCA 
To confirm our finding that αAR signaling modifies SERCA via an 
OPTM at C674, we tested whether another Gαq-stimulus, PO, was also 
capable of mediating this modification. As hypertrophy is attenuated in 
both in vitro and in vivo models of C674S SERCA, we hypothesized that 
redox-activation of SERCA was a necessary component of hypertrophic 
stimulation. We looked at irreversible sulfonylation and maximal activity 
to assess SERCA oxidation and function in the hypertrophic phase of PO. 
5.2.4.1. C674 SERCA sulfonylation 
Because OPTM on SERCA has been shown to be a crucial 
regulator of SERCA activity, we assessed an irreversible 
modification using an antibody specifically directed against C674-
sulfonylated SERCA (SERCA-SO3H). While our laboratory has 
shown that SERCA-SO3H is increased with 12-weeks of pressure 
overload, histological analysis revealed no differences in SERCA-
SO3H between WT sham and AAC hearts at 3 weeks. Similarly, SKI 
did not affect the level of SERCA-SO3H staining at this time point, 
and was likewise not increased with AAC. These data suggest that 
while AAC-induced hypertrophy is SERCA C674-dependent, it is 
likely via a reversible modification at this early time point.  
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Figure 29. AAC does not cause irreversible SERCA sulfonylation at 3 weeks. 
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5.2.5. SERCA function in early-stage AAC 
Central to the thesis of this work, we propose that redox 
modification of SERCA alters its function. This has been observed in 
various cell types and has been reviewed at length in section 1.4. While 
reversible glutathiolation of SERCA is known to increase its activity in 
ARVM, decreased SERCA function is a frequently reported response in 
the decompensated stages of pressure overload-induced failure. Our 
laboratory has shown that this decrease in function is associated with 
irreversible SERCA-SO3H in cardiac tissue at 12 weeks post AAC. 
Because SERCA function is typically studied late in the progression of 
failure, we tested whether decreased SERCA function associated with 
irreversible SERCA-SO3H was present at 3 weeks, to confirm our finding 
that C674-dependent hypertrophy in 3-week AAC mice is not mediated by 
irreversible sulfonylation. 
We measured SERCA activity using a non-reducing, radioactive 
maximal calcium uptake assay in SERCA-enriched microsomes. This 
method does not detect alterations in the calcium-binding affinity of 
SERCA (Kd) at physiological conditions, but does measure the maximal 
stimulated activity (Vmax) of the enzyme, which is known to be decreased 
in PO-induced heart failure. We found no significant decreases in 45[Ca2+] 
uptake with AAC at 3 weeks in either WT or SKI mice. Similarly, SKI did 
not alter or prevent changes in maximal SERCA activity compared to WT 
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(n = 6-14). These data suggest that 3-week AAC does not alter SERCA 
function via irreversible sulfonylation at C674.  
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Figure 30. SERCA activity is not decreased following 3-week AAC. 
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5.3. Discussion 
5.3.1. Protective effects of redox-insensitive SERCA on LVH 
While redox-insensitive SERCA exerted a strong anti-hypertrophic 
effect on mouse hearts, it did not completely inhibit the PO response. 
Because αAR-mediated MAPK signaling was completely blunted in 
isolated CM from SKI mice, other hypertrophic pathways regulated by PO 
are likely activated but SERCA-independent. Interestingly, PO in our 
transgenic model of redox-insensitive SERCA attenuated LVH to 
comparable levels as overexpression of the antioxidant pCAT. This 
suggests two possibilities: (1) that SERCA is a crucial mediator of ROS-
associated hypertrophy in PO, or (2) that redox regulation of SERCA is 
upstream of oxidant production and SERCA oxidation potentiates a pro-
oxidant effect. Taken with in vitro data from ARVM, we hypothesize that 
redox-regulation of SERCA plays a critical role in the MAPK signaling 
pathway, which is activated in PO, and C674S mediates its anti-
hypertrophic effects by downregulating signal transduction via PP2A 
activation. 
In addition, it appears that while PO attenuates cardiac hypertrophy 
as measured by heart weight and total wall thickness, concentric 
hypertrophy as measured by myocyte diameter was completely prevented 
in SKI mice. Because fibrosis was not significantly decreased in SKI vs 
WT mice, this suggests that both eccentric and concentric growth of CM 
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may be occurring in this model, and that the MAPK pathways inhibited by 
SERCA C674S may preferentially favor concentric growth. 
5.3.2. Markers of decompensated failure are not observed early in AAC 
We validated our 3-week AAC model with echocardiographic 
measurements to establish a role for redox-mediated SERCA regulation of 
LVH in the hypertrophic phase of PO, before overt failure is observed. 
Systolic dysfunction does not appear to be present at this early time point, 
and the only significant differences in echocardiograms were related to 
concentric thickening of the heart wall. Similarly, oxidative stress was 
comparatively low at this stage of PO, which induced reversible OPTM, 
but not the severe, global oxidative stress associated with irreversible 
OPTM which occur late in the progression of PO-induced failure. 
5.3.3. Role of reversible OPTM of SERCA in pathogenesis of LVH 
Modifying the Kd of SERCA through isoform switch has been 
shown to cause hypertrophy as described in section 1.4. The C674 moiety 
lies on the hinge domain of SERCA71,74 and SERCA modification of this 
site may result in conformational changes that similarly alter its Ca2+ 
affinity. Our data reveal that C674-dependent hypertrophy in AAC is not 
characterized by irreversible sulfonylation or decreases in Vmax of SERCA 
activity. This indicates that C674 oxidation induced by 3-week AAC is 
likely an activating, reversible modification with the potential to mediate 
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calcium-dependent signaling changes in CM hypertrophy. 
5.3.4. Conclusion 
Interfering with endogenous pathways governing LVH has been 
shown to either prevent or accelerate the progression to failure. Our model 
appears to prevent LVH without increasing parameters of cardiac 
dysfunction. PO-induced hypertrophy was SERCA C674-dependent, and 
mediated effects similar to overexpression of an antioxidant. C674 
oxidation therefore appears to be an important redox switch regulating the 
pro-hypertrophic MAPK signaling pathway via an OPTM. Two 
possibilities are likely: SERCA is activated via reversible glutathiolation, 
or inhibited via irreversible sulfonylation. We found that our PO stimulus 
did not oxidatively modify SERCA C674 in a manner consistent with 
inactivating, irreversible sulfonylation. This leads us to conclude that 
reversible redox activation of SERCA is an important regulator of LVH in 
Gαq-mediated growth pathways in the CM. 
Hypertrophy was completely inhibited in our isolated cell culture 
system, but only partially inhibited in the mouse model. The reasons for 
this are likely twofold; 1) the use of an overexpression system in ARVM 
vs the specific knock-in mutation of endogenously expressed SERCA in 
SKI mice, and 2) the difference in isoform specificity between the two 
systems. ARVM in culture overexpress WT or C674S SERCA2 10-12 
fold (see Fig. 1) compared to the mouse model, which expresses 
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endogenous levels of SERCA. While both models utilize a similarly 
mutated model of redox-insensitive SERCA, the over-expression system 
has a considerably higher ratio of mutated:WT SERCA than the SKI 
mouse. Given the anti-hypertrophic effects of C674S SERCA in both 
ARVM and mice, this overexpression is likely to account for the more 
severe blunting of hypertrophy observed in αAR-stimulated ARVM 
expressing C674S than PO SKI mice. Secondly, both WT and C674S 
SERCA overexpressed in ARVM are based on the human SERCA2b 
isoform, which has a higher calcium affinity than the SERCA2a isoform 
predominantly expressed in cardiac myocytes. The mutation introduced 
into the transgenic mouse model introduces a mutation into the SERCA2 
gene at C674, which is present in both splice variants. Due to the 
propensity for SERCA2b isoforms to mediate hypertrophy as outlined in 
section 1.5, it is likely that the presence of higher-affinity WT and redox-
insensitive SERCA contribute to a greater hypertrophic disparity in vitro 
than that seen in the more physiological mouse model with endogenously 
expressed isoforms.  
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6. ALTERNATE MODELS INDUCING OPTM OF SERCA 
While Gαq-mediated hypertrophy as studied in αAR and PO models was the 
main focus of this work, several in vitro and in vivo models of increased oxidative 
stress induce OPTM of SERCA at C674, including nitric oxide (NO) signaling, 
growth factor stimulation, and metabolic disorders, as described in section 1.4. We 
studied in vitro and in vivo effects of Gαq-independent models of SERCA oxidation to 
further expand our knowledge revealing SERCA C674 as a key regulator of CM 
hypertrophy. 
6.1. Peroxynitrite 
NO is arguably the mostly widely known free radical species with an 
accepted signaling effect in cardiovascular systems. NO radicals released by 
NOS from endothelium activate guanylate cyclase, which through its second 
messenger cyclic-GMP activates protein kinase G and decreases vascular smooth 
muscle cell tone by promoting calcium uptake. This potent vasodilator effect has 
been put to immense use clinically, with NO donors like nitroglycerin and 
isosorbide often given as first-line, fast acting therapies to acutely reduce 
myocardial ischemia or HTN. In addition, by relaxing myofilaments through the 
sequestration of [Ca2+]i, it argues a role for NO-signaling on SERCA, which has 
been shown via S-glutathiolation of C674. This intermediate is thought to occur 
through a rapid, local interaction with the ROS superoxide (O2-) to form the 
intermediate peroxynitrite (ONOO). This unstable intermediate has a high 
propensity to adduct to reactive thiol groups, which undergo rapid enzymatic 
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exchanges with reduced glutathione (GSH) to form a S-glutathiolation OPTM. 
Because this stimulus activates SERCA activity, we tested whether direct 
stimulation with the oxidant ONOO induces an increase in SERCA-mediated 
calcium uptake in ARVM. We observed maximal thapsigargin-sensitive calcium 
uptake in microsomes isolated from ARVM treated with varying concentrations 
of ONOO in non-reducing conditions in vitro. Increasing concentrations were 
negatively correlated with SERCA function, which was significantly inhibited at 
75 µM (53 ± 19%, p < 0.05) compared to vehicle control (n = 6). This indicates 
that ONOO inhibits SERCA at these concentrations, possibly due to 
sulfonylation. Regardless, these data indicate these concentrations of ONOO 
were not a model for Gαq-mediated glutathiolation of SERCA in ARVM. 
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Figure 31. ONOO does not stimulate SERCA activity in ARVM. 
0 .
3  
M
 N
aO
H
2 5
 u
M
 O
N O
O
5 0
 u
M
 O
N O
O
7 5
 u
M
 O
N O
O
0
5
1 0
1 5
2 0
n
m
o
l 
C
a
/m
in
/m
g
 p
ro
te
in
*
 
 
  
		
107 
6.2. Aging 
Aging is an important model of cardiac decline, and is the number one 
most significant risk factor for HTN, LVH, and diastolic dysfunction. Notably, 
aging is associated with generation of ROS171 and altered SERCA function.172 
Aged AMVM have documented decreases in SERCA activity.173 Because of this, 
we were interested if SKI mice had preserved SERCA function in 2 year-aged 
mice. We tested maximal 45[Ca2+] uptake in microsomes isolated from WT and 
SKI hearts to determine whether aging in the absence of other ROS-producing 
stressors would be sufficient to redox-regulate SERCA function. We found no 
significant differences between young or aged mice, and no measurable effect of 
C674S expression on SERCA activity (n = 4-7). These data suggest that aging in 
isolation is not sufficient to cause ROS-inhibition of SERCA function. 
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Figure 32. Aging does not inhibit maximal SERCA function. 
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6.3. Discussion 
SERCA C674 is a sensitive site susceptible to both reversible and 
irreversible modifications under oxidizing conditions. Direct oxidant 
modification in vitro as well as aging processes in vivo were proposed to alter 
SERCA OPTM and function. We found that treating SERCA with varying 
concentrations of ONOO induced a dose dependent decrease in SERCA activity, 
indicating a role for an irreversible modification due to C674 sulfonlyation, or 
nonspecific oxidation of SERCA and/or its effector molecules. Conversely, aging 
did not have an inhibitory effect on SERCA function in WT or SKI mice. 
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7. MEASURING INTRAORGANELLE CALCIUM WITH THE DUAL-
FLUORESCENT DYE CAMELEON 
7.1. Rationale 
Both intracellular calcium ([Ca2+]i) and calcium stores are tightly regulated in 
CM. In ARVM, SERCA pumps Ca2+ ions from a common cystolic pool into the 
ER/SR. Other calcium transporters compete with SERCA for uptake of free 
intracellular Ca2+, chiefly the mitochondrial calcium uniporter (MCU) and the 
sarcolemmal and mitochondrial sodium/calcium exchangers (NCX).174 Indeed, these 
transporters may occur locally coupled in specific microdomains, tethered to both ER 
and SR compartments, facilitating IP3R- and RyR-mediated calcium release to 
mitochondria.175 Such a mechanism has been suggested to be important for calcium 
regulation of growth signaling176 and energetic coupling via βAR.177,178 In fact, recent 
reports even show an association between hypertrophy and decreased energetics.179 
These findings suggest that calcium regulation of growth pathways by SERCA may 
also involve the mitochondria. Combined with our data proposing redox-modification 
of SERCA in regulating growth, we wanted to observe the direct intra-organellar 
effects of αAR signaling on ER/SR and mitochondrial calcium. Fura-2 is only capable 
of measuring intracellular calcium in intact cell systems, and use of calcium 
indicators to measure mitochondrial calcium such as the acetoxymethyl (AM) 
conjugated dye Rhod-2 have been questioned due to cytosolic retention and lack of 
localization specificity.180 Secondly, non-ratiometric dyes are subject to artifacts 
related to unequal loading or poor calibration. We elected to use the genetically-
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encoded ratiometric calcium indicator cameleon to measure local changes in ARVM 
ER/SR and mitochondrial calcium by generating adenoviral constructs as outlined in 
section 2.2. The cameleon fluorescent indicator is composed of two fluorescent 
proteins, cyan-emitting (CFP) and yellow-emitting (citrine/cpVenus), linked by the 
calcium-binding element calmodulin (CaM).181 Calcium binding to the CaM domain 
initiates conformational changes, which bring the fluorescent proteins into proximity, 
and facilitate fluorescence resonance energy transfer (FRET). Effectively, calcium 
binding causes an increase in FRET between the two fluorescent proteins, measured 
as increased yellow channel emission coupled to decreased cyan channel emission 
upon excitation. Therefore, increases in (citrine/cpVenus:CFP) ratios are associated 
with increases in local [Ca2+]. These indicators have not been described in isolated 
adult CM models, and we sought to evaluate their efficacy in ARVM as well as 
AMVM from transgenic mouse models via adenoviral and adeno-associated viral 
infection, respectively. 
Due to their expression by endogenous cellular machinery, cameleons can be 
directed to various compartments within the cell by linkage to organelle-specific 
localization sequences. We used the D1ER and 4mtD3cpv cameleon isoforms to 
measure inducible changes in [Ca2+] in ER/SR and mitochondrial compartments, 
respectively. D1ER is localized to the ER/SR via a 5’ calreticulin leader sequence and 
3’ ER retention sequence. This probe has a dual Kd at 0.81 and 60 µM [Ca2+],182 
which is consistent with detection of SR [Ca2+] content, estimated to range from 80 – 
100 µM in resting and oscillating CM, with large downward fluxes (70 µM) with 
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caffeine-induced calcium release via RyR.183 To measure mitochondrial calcium, we 
used the 4mtD3cpv probe, which localizes to the mitochondria via its four tandem 
signal sequences (4mt) from the mitochondrial subunit VII of human cytochrome C 
oxidase.184 This probe has a dynamic range and a Kd for [Ca2+] of 600 nM,185 which is 
consistent with detection of mitochondrial [Ca2+] in ARVM, which range from 100 
nM at baseline up to 500 nM with adrenergic stimulation.186 
7.2. Experimental design 
Both caffeine and the βAR-agonist isoproterenol have been shown to induce 
rapid mitochondrial calcium uptake through the high-affinity MCU in AMVM, which 
has been proposed to regulate energetics relevant to SERCA function.187 Caffeine is 
also a classical agonist for dumping SR [Ca2+] stores via the RyR. We therefore used 
this stimulus to test the ability of cameleon expression to detect large changes in 
SR/ER and mitochondrial [Ca2+] content, in order to confirm their efficacy for 
measurements using physiologic stimuli. Emission data is presented as ratios 
normalized to baseline emission, with citrine:CFP in D1ER-infected cells and 
cpVenus:CFP in 4mtD3cpv-infected ARVM. 
7.2.1. Adenoviral constructs for expression in ARVM in vitro 
The calcium response to caffeine (20 mM) was measured in 
ARVM expressing D1ER and 4mtD3cpv cameleon probes to observe 
associated changes in calcium stores in both ER/SR and mitochondrial 
compartments. Caffeine is known to induce emptying of SR stores into the 
cytosol by the RyR, which has been described to subsequently enter the 
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mitochondria after [Ca2+]i levels rise via the MCU. Our initial findings 
suggest that cameleon was able to detect calcium fluxes, as emission ratios 
immediately fell in D1ER-expressing ARVM with caffeine application, 
while 4mtD3cpv-expressing ARVM were characterized by an initial rise 
followed by calcium washout. Unfortunately, duplication of these 
experiments with appropriate controls showed that ARVM exhibited 
similar decreases in emission ratios without caffeine application. We 
observed cells release calcium and hypercontract in the absence of this 
stimulus, which we associated with over-excitation under high power and 
frequent, long exposure times (n = 5). Unfortunately, these parameters 
were necessary to visualize D1ER (Fig. 27). The 4mtD3cpv probe 
expresses at much higher intensity with high specificity (Fig. 28), allowing 
us to diminish this artifact with smaller exposures under lower power. We 
studied ARVM expressing 4mtD3cpv following 20 mM caffeine 
application at low (10% power, 5 ms) and high (50%, 25 ms) exposures. 
Decreasing the intensity and exposure time removed this artifact, but did 
not indicate the expected increases in mitochondrial [Ca2+] with caffeine 
(n = 10).  
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Figure 33. D1ER expression in ARVM. 
 
D1ER emission in citrine (top) and CFP (bottom) channels. 
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Figure 34. 4mtD3cpv is highly expressed and localized to mitochondria chains. 
 
4mtD3cpv emission in cpVenus (top) and CFP (bottom) channels. 
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Figure 35. Decreases in ER/SR calcium are caffeine-independent. 
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Figure 36. Decreasing exposure preserves mitochondrial calcium. 
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7.2.2. AAV for use in transgenic mouse models in vitro 
Simultaneous with development of our adenoviral constructs for 
use in ARVM, we cloned cameleon D1ER and 4mtD3cpv into AAV 
vectors directed to the CM for use in mouse models. AAV was injected 
into mice via tail vein and isolated AMVM were studied after two weeks. 
Preliminary experiments in mice injected with 4mtD3cpv showed 
incremental increases in mitochondrial calcium with caffeine application, 
represented as cpVenus:CFP emission ratio and heat-map imaging 
corresponding to 30s time points with caffeine added immediately after 
time 0 (Fig 37, n = 2). We limited exposure times and frequency as per our 
ARVM experiments to diminish artifacts in this pilot experiment. 
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Figure 37. Mitochondrial calcium increases with caffeine application in AMVM. 
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7.3. Discussion 
At the time of writing, validation and calibration of the cameleon probes 
are still ongoing in both ARVM and mouse models. We developed these tools 
with hopes of visualizing changes in ER/SR and mitochondrial calcium with 
physiological stimuli. The ability to study calcium stores directly in non-
contracting cells is an important strategy to distinguish SERCA function in the 
setting of large calcium fluxes observed in ECC from small, localized changes in 
calcium in our isolated CM models of αAR signaling. Gαq-mediated hypertrophy 
is dependent on reversible OPTM of C674 of SERCA, and we hypothesize that 
this OPTM activates SERCA, increases calcium uptake, and decreases PP2A 
activity. Direct measurements of SR and intracellular calcium are necessary to 
confirm this hypothesis. 	
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